###begin article-title 0
###xml 56 77 56 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus</italic>
###xml 107 108 107 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn1">*</xref>
###xml 108 108 108 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn2"/>
###xml 108 110 108 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn3">S&#8414;</xref>
###xml 56 77 <span type="species:ncbi:1280">Staphylococcus aureus</span>
Structure-Function Analysis of the C3 Binding Region of Staphylococcus aureus Immune Subversion Protein Sbi*Sâƒž
###end article-title 0
###begin p 1
Supported by a BBSRC Ph.D. studentship.
###end p 1
###begin p 2
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 98 117 98 117 <email xmlns:xlink="http://www.w3.org/1999/xlink">bssjmhve@bath.ac.uk</email>
###xml 119 120 119 120 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 217 233 217 233 <email xmlns:xlink="http://www.w3.org/1999/xlink">bsssb@bath.ac.uk</email>
2 To whom correspondence may be addressed. Tel.: 44-0-1225-383639; Fax: 44-0-1225-386779; E-mail: bssjmhve@bath.ac.uk. 3 To whom correspondence may be addressed. Tel.: 44-0-1225-386436; Fax: 44-0-1225-386779; E-mail: bsssb@bath.ac.uk.
###end p 2
###begin p 3
###xml 0 15 0 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Author's Choice</italic>
Author's Choice
###end p 3
###begin p 4
 applies to Author Choice Articles
###end p 4
###begin p 5
###xml 30 51 30 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus</italic>
###xml 694 703 694 703 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus</italic>
###xml 752 753 752 753 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 755 757 755 757 <sup xmlns:xlink="http://www.w3.org/1999/xlink">15</sup>
###xml 30 51 <span type="species:ncbi:1280">Staphylococcus aureus</span>
###xml 694 703 <span type="species:ncbi:1280">S. aureus</span>
###xml 1412 1417 <span type="species:ncbi:9606">human</span>
###xml 1545 1551 <span type="species:ncbi:9606">humans</span>
Among the recently discovered Staphylococcus aureus immune evasion proteins, Sbi is unique in its ability to interact with components of both the adaptive and innate immune systems of the host. Sbi domains I and II (Sbi-I and Sbi-II) bind IgG. Sbi domain IV (residues 198-266) binds the central complement protein C3. When linked to Sbi-III, Sbi-IV induces a futile consumption of complement via alternative pathway activation, whereas isolated Sbi-IV specifically inhibits the alternative pathway without complement consumption. Here we have determined the three-dimensional structure of Sbi-IV by NMR spectroscopy, showing that Sbi-IV adopts a three-helix bundle fold similar to those of the S. aureus complement inhibitors Efb-C, Ehp, and SCIN. The 1H-15N HSQC spectrum of Sbi-III indicates that this domain, essential for futile complement consumption, is natively unfolded, at least when isolated from the rest of Sbi. Sbi-IV and Sbi-III-IV both bind C3dg with 1:1 stoichiometry and submicromolar affinity. Despite low overall sequence identity, Sbi possesses the same residues as Efb at two positions essential for Efb-C binding to C3d. Mutation to alanine of either of these residues, Arg-231 and Asn-238, abolishes both Sbi-IV binding to C3dg and Sbi-IV alternative pathway inhibition. The almost complete conservation of Sbi-III and Sbi-IV amino acid sequences across more than 30 strains isolated from human and animal hosts indicates that the unique mechanism of Sbi in complement system subversion is a feature of infections of both humans and economically important animals.
###end p 5
###begin p 6
###xml 0 206 0 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">The atomic coordinates and structure factors (codes 2jvg and 2jvh) have been deposited in the Protein Data Bank, Research Collaboratory for Structural Bioinformatics, Rutgers University, New Brunswick, NJ (<ext-link ext-link-type="uri" xlink:href="http://www.rcsb.org/">http://www.rcsb.org/</ext-link>).</italic>
The atomic coordinates and structure factors (codes 2jvg and 2jvh) have been deposited in the Protein Data Bank, Research Collaboratory for Structural Bioinformatics, Rutgers University, New Brunswick, NJ ().
###end p 6
###begin p 7
###xml 27 41 27 41 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink">Wellcome Trust</grant-sponsor>
###xml 48 54 48 54 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink">076124</grant-num>
###xml 67 130 67 130 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink">Biotechnology and Biological Sciences Research Council Research</grant-sponsor>
###xml 137 148 137 148 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink">BBS/B/12121</grant-num>
###xml 177 215 177 215 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink">Canadian Institutes of Health Research</grant-sponsor>
###xml 222 230 222 230 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink">MOP-7081</grant-num>
###xml 387 400 387 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink">advertisement</italic>
This work was supported by Wellcome Trust Grant 076124 (to S. B.), Biotechnology and Biological Sciences Research Council Research Grant BBS/B/12121 (to J. M. H. v. d. E.), and Canadian Institutes of Health Research Grant MOP-7081 (to D. E. I.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
###end p 7
###begin p 8
###xml 0 15 0 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Author's Choice</italic>
Author's Choice-Final version full access.
###end p 8
###begin p 9
The on-line version of this article (available at ) contains supplemental Figs. S1-S3.
###end p 9
###begin p 10
###xml 0 21 0 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus</italic>
###xml 250 259 250 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus</italic>
###xml 444 445 444 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref1">1</xref>
###xml 541 542 541 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref2">2</xref>
###xml 543 544 543 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref4">4</xref>
###xml 658 659 658 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref5">5</xref>
###xml 660 661 660 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref7">7</xref>
###xml 1565 1566 1565 1566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref8">8</xref>
###xml 0 21 <span type="species:ncbi:1280">Staphylococcus aureus</span>
###xml 47 53 <span type="species:ncbi:9606">humans</span>
###xml 250 259 <span type="species:ncbi:1280">S. aureus</span>
Staphylococcus aureus is a common commensal of humans but can cause illnesses ranging from superficial skin infections to serious invasive infections such as septic arthritis, osteomyelitis, and endocarditis. The broad spectrum of diseases caused by S. aureus reflects not only an ability to colonize different tissues through an array of surface-bound adhesins (MSCRAMMS or microbial surface components recognizing adhesive matrix molecules) (1) but also to circumvent various immune surveillance systems, among them the complement system (2-4). Complement comprises a finely regulated cascade of proteins that links the innate and adaptive immune systems (5-7). The complement system both eliminates bacterial cells directly via the membrane attack complex and recruits effector molecules that label bacterial cells and target them for destruction by immune effector cells, for example neutrophils. This process of complement fixation occurs via two specific recognition pathways: the lectin pathway, which is a component of innate immunity and the classical pathway, which requires specific interaction with antibodies bound to antigens on target cells. The lectin and classical pathways are amplified by the alternative pathway, although the alternative pathway may also initiate on a target independent of the classical and lectin pathways. All three pathways converge on the complement protein C3, which has two disulfide-linked polypeptide chains and various proteolytic derivative forms that correspond to different intermediates in the activation cascade (8).
###end p 10
###begin p 11
###xml 134 135 134 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref9">9</xref>
###xml 161 170 161 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus</italic>
###xml 333 334 333 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn5">4</xref>
###xml 433 435 433 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref10">10</xref>
###xml 436 438 436 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref13">13</xref>
###xml 599 601 599 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref14">14</xref>
###xml 700 716 700 716 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Escherichia coli</italic>
###xml 718 720 718 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref15">15</xref>
###xml 746 755 746 755 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus</italic>
###xml 821 823 821 823 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref16">16</xref>
###xml 824 826 824 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref20">20</xref>
###xml 882 891 882 891 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus</italic>
###xml 1010 1012 1010 1012 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref17">17</xref>
###xml 1014 1016 1014 1016 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref20">20</xref>
###xml 161 170 <span type="species:ncbi:1280">S. aureus</span>
###xml 700 716 <span type="species:ncbi:562">Escherichia coli</span>
###xml 746 755 <span type="species:ncbi:1280">S. aureus</span>
###xml 882 891 <span type="species:ncbi:1280">S. aureus</span>
Numerous proteins from microbial pathogens that target the complement cascade at several points have been discovered in recent years (9), including several from S. aureus. These include the extracellular fibrinogen-binding protein (including the N-terminal fibrinogen binding domain and C-terminal complement inhibitory domain; Efb),4 Ehp, SCIN, and SSL7. Efb and Ehp bind to C3 and reduce its availability at the bacterial surface (10-13). SCIN interacts with the classical and alternative pathway C3 convertases C4b2a and C3bBb at a bacterial surface and thereby reduces their enzymatic activity (14). SSL7 binds complement factor C5 and inhibits complement-mediated hemolysis and serum-killing of Escherichia coli (15). There are also several S. aureus proteins that inhibit neutrophil movement to the infection site (16-20). Among these, CHIPS (chemotaxis inhibitory protein of S. aureus) blocks the neutrophil receptors for the major chemoattractants C5a (a by-product of complement activation) and fMLP (17, 20).
###end p 11
###begin p 12
###xml 8 17 8 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus</italic>
###xml 95 97 95 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref21">21</xref>
###xml 107 108 104 105 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 133 135 130 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref22">22</xref>
###xml 198 207 195 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus</italic>
###xml 401 405 398 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XXXX</italic>
###xml 564 578 561 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus</italic>
###xml 606 615 603 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus</italic>
###xml 637 638 634 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref2">2</xref>
###xml 708 709 705 706 <italic xmlns:xlink="http://www.w3.org/1999/xlink">X</italic>
###xml 785 794 782 791 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus</italic>
###xml 875 877 872 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref23">23</xref>
###xml 8 17 <span type="species:ncbi:1280">S. aureus</span>
###xml 198 207 <span type="species:ncbi:1280">S. aureus</span>
###xml 283 287 <span type="species:ncbi:1280">MRSA</span>
###xml 606 615 <span type="species:ncbi:1280">S. aureus</span>
###xml 785 794 <span type="species:ncbi:1280">S. aureus</span>
Another S. aureus immune subversion protein, Sbi, was originally identified as an IgG-binding (21) and beta2-glycoprotein-I-binding (22) protein. Sbi is a 436-amino acid protein that occurs in many S. aureus strains, including methicillin-sensitive (MSSA) and methicillin-resistant (MRSA) strains. From its N terminus, Sbi comprises four small domains up to residue 266 followed by eight copies of a PXXXX repeat motif with a high concentration of glutamine, lysine, aspartate, valine, and isoleucine and then a C-terminal tyrosine-rich 130-residue region. Unlike Staphylococcus protein A, the other known S. aureus IgG-binding protein (2), Sbi lacks the typical Gram-positive cell wall-anchoring sequence LPXTG. Indeed, evidence using Western blots of fractionated cells from several S. aureus strains, including Newman, indicates that most Sbi is secreted into the medium (23).
###end p 12
###begin p 13
###xml 201 203 201 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref24">24</xref>
###xml 309 311 309 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref23">23</xref>
###xml 774 776 774 776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref23">23</xref>
We have recently demonstrated that Sbi is a multifunctional protein that not only interferes directly with the adaptive immune system through its two N-terminal IgG binding domains (Sbi-I and Sbi-II) (24), but also modulates the innate immune system through its third and fourth domains (Sbi-III and Sbi-IV) (23). Specifically, Sbi binds complement protein C3 through Sbi-IV interaction with C3 subunits C3dg and C3a and induces a futile consumption of complement predominantly via fluid phase activation of the alternative pathway. Sbi fragments containing domains I-II-III-IV (Sbi-E) and III-IV induce this futile consumption of complement, whereas isolated Sbi-IV does not. Sbi-IV is nevertheless strongly inhibitory in an assay measuring alternative pathway activation (23).
###end p 13
###begin p 14
###xml 126 128 126 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref12">12</xref>
###xml 136 138 136 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref13">13</xref>
###xml 147 149 147 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref25">25</xref>
###xml 172 174 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref26">26</xref>
Here, we have determined the solution structure of Sbi-IV, showing that it resembles the structures of Efb C-terminal domain (12), Ehp (13), SCIN (25), and domains of SpA (26). Site-directed mutagenesis, binding experiments, and complement assays have been carried out to investigate the role of Sbi-IV in Sbi subversion of the complement system.
###end p 14
###begin title 15
EXPERIMENTAL PROCEDURES
###end title 15
###begin p 16
###xml 0 66 0 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cloning, Expression, and Purification of Recombinant Sbi Fragments</italic>
###xml 140 149 140 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus</italic>
###xml 272 274 272 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref27">27</xref>
###xml 302 304 302 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref23">23</xref>
###xml 306 308 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref24">24</xref>
###xml 357 364 357 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 421 422 415 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 422 425 416 419 <sub xmlns:xlink="http://www.w3.org/1999/xlink">600</sub>
###xml 499 500 490 491 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d</sc>
###xml 537 538 528 529 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 571 573 562 564 <sup xmlns:xlink="http://www.w3.org/1999/xlink">15</sup>
###xml 595 597 586 588 <sup xmlns:xlink="http://www.w3.org/1999/xlink">15</sup>
###xml 611 613 602 604 <sup xmlns:xlink="http://www.w3.org/1999/xlink">15</sup>
###xml 615 617 606 608 <sup xmlns:xlink="http://www.w3.org/1999/xlink">13</sup>
###xml 706 708 697 699 <sup xmlns:xlink="http://www.w3.org/1999/xlink">15</sup>
###xml 710 711 701 702 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 718 720 709 711 <sup xmlns:xlink="http://www.w3.org/1999/xlink">15</sup>
###xml 722 723 713 714 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 726 728 717 719 <sup xmlns:xlink="http://www.w3.org/1999/xlink">13</sup>
###xml 729 730 720 721 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 731 732 722 723 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d</sc>
###xml 922 923 913 914 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 1232 1233 1222 1223 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 140 149 <span type="species:ncbi:1280">S. aureus</span>
###xml 228 231 <span type="species:ncbi:12227?0.9375">TEV</span>
###xml 357 364 <span type="species:ncbi:562">E. coli</span>
###xml 1344 1347 <span type="species:ncbi:12227?0.9375">TEV</span>
###xml 1439 1442 <span type="species:ncbi:12227?0.9375">TEV</span>
###xml 1528 1531 <span type="species:ncbi:12227?0.9375">TEV</span>
Cloning, Expression, and Purification of Recombinant Sbi Fragments-DNA sequences encoding several Sbi fragments were amplified by PCR using S. aureus strain Mu50 genomic DNA as template and cloned into a pET-based vector with a TEV-cleavable N-terminal hexahistidine tag (27), as described previously (23, 24). The resulting plasmids were used to transform E. coli strain BL21(DE3). Cells were grown at 37 degreesC to an A600 value of 0.6 when they were induced by addition of isopropyl-1-thio-beta-d-galactopyranoside (Melford) to 0.2 mm and cultured for a further 4 h. 15N-labeled Sbi-III and 15N-labeled and 15N/13C-labeled Sbi-IV for NMR spectroscopy were produced by expression in minimal medium with 15NH4Cl and 15NH4Cl/13C6-d-glucose (Spectra Stable Isotopes) as the sole nitrogen and nitrogen/carbon sources. Following cell harvest by centrifugation and lysis by sonication, the lysate was centrifuged at 40,000 x g for 15 min, and the supernatant filtered through a 0.45-mum filter. Sbi fragments were purified by nickel ion-chelating chromatography using a 1-ml HisTrap column attached to anAKTA purifier (GE Healthcare). The column was then washed with binding buffer, and the bound proteins were eluted using a 0.05-1.0 m imidazole gradient. For NMR data acquisition, the N-terminal hexahistidine tag was removed by incubation with TEV protease (Invitrogen), and the hexahistidine tag-free Sbi fragment was then separated from TEV protease (itself His-tagged) by a second passage through a HisTrap column. Following TEV removal of the hexahistidine tag, the Sbi proteins contained N-terminal residues GAM from the expression vector.
###end p 16
###begin p 17
###xml 0 64 0 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NMR Sample Generation and NMR Spectroscopy of Sbi-III and Sbi-IV</italic>
###xml 116 117 116 117 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 128 129 128 129 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 139 140 139 140 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 150 151 150 151 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 354 355 348 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">z</italic>
###xml 451 453 445 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref28">28</xref>
###xml 489 491 483 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref29">29</xref>
###xml 764 766 758 760 <sup xmlns:xlink="http://www.w3.org/1999/xlink">15</sup>
###xml 825 826 819 820 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 868 870 862 864 <sup xmlns:xlink="http://www.w3.org/1999/xlink">15</sup>
###xml 876 878 870 872 <sup xmlns:xlink="http://www.w3.org/1999/xlink">13</sup>
###xml 931 933 925 927 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref30">30</xref>
###xml 996 998 990 992 <sup xmlns:xlink="http://www.w3.org/1999/xlink">15</sup>
###xml 1050 1052 1044 1046 <sup xmlns:xlink="http://www.w3.org/1999/xlink">13</sup>
NMR Sample Generation and NMR Spectroscopy of Sbi-III and Sbi-IV-Purified Sbi-III and Sbi-IV were exchanged into 5 mm MES, 100 mm NaCl, 1 mm EDTA, 1 mm benzamidine, pH 5.5. All NMR data were acquired at 16 degreesC on a Varian Unity INOVA spectrometer operating at a nominal proton frequency of 600 MHz, using a triple resonance 5-mm probe equipped with z-axis-pulsed-field gradients. NMR data were processed using the NMRPipe/NMRDraw software suite (28) and analyzed using CCPN Analysis (29). Sequence-specific backbone resonance assignments of Sbi-IV were made using three-dimensional HNCACB, CBCA(CO)NH, HNCO, HN(CA)CO, HNHA, and HBHA(CBCACO)NH data sets. Side chain resonance assignments of Sbi-IV were made using CCC-TOCSY-NNH, HCC-TOCSY-NNH, HCCH TOCSY, and 15N-edited TOCSY (12.1, 12.1, 15.6, and 50 ms mixing times). 1H chemical shifts were referenced to DSS. 15N and 13C chemical shifts were referenced indirectly to DSS (30). Sbi-IV NOE distance restraints were obtained by analysis of 15N-NOESY HSQC (50, 100, and 150 ms mixing times) and 13C-NOESY HSQC (70 and 175 ms mixing times) spectra. All pulse sequences were from the Varian BioPack suite of pulse sequences.
###end p 17
###begin p 18
###xml 0 21 0 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Structure Calculation</italic>
###xml 238 239 234 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 239 241 235 237 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6</sup>
###xml 242 246 238 242 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1/6</sup>
###xml 252 254 248 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref31">31</xref>
###xml 314 316 306 308 <sup xmlns:xlink="http://www.w3.org/1999/xlink">13</sup>
###xml 317 322 309 310 <sub xmlns:xlink="http://www.w3.org/1999/xlink">&#945;</sub>
###xml 324 326 312 314 <sup xmlns:xlink="http://www.w3.org/1999/xlink">13</sup>
###xml 327 331 315 316 <sub xmlns:xlink="http://www.w3.org/1999/xlink">&#946;</sub>
###xml 333 335 318 320 <sup xmlns:xlink="http://www.w3.org/1999/xlink">13</sup>
###xml 339 340 324 325 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 341 346 326 327 <sub xmlns:xlink="http://www.w3.org/1999/xlink">&#945;</sub>
###xml 361 363 342 344 <sup xmlns:xlink="http://www.w3.org/1999/xlink">15</sup>
###xml 394 396 375 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref32">32</xref>
Structure Calculation-NOE peak intensities were converted to distance restraints within Analysis. Distances involving methyl groups, aromatic ring protons, and non-stereospecifically assigned methylene protons were represented as a (Sigmar-6)-1/6 sum (31). Backbone dihedral angles phi and Psi were predicted from 13Calpha, 13Cbeta, 13C', 1Halpha, and backbone 15N chemical shifts using TALOS (32). The phi dihedral angles were restrained to TALOS-predicted values +/-30degrees or +/-40degrees, and Psi dihedral angles were restrained to TALOS-predicted values +/-50degrees. Hydrogen bond distance restraints were established from NOE patterns, and the proximities of donor and acceptor groups in structures calculated using NOE-derived distance restraints. For hydrogen bond restraints, the NH-O distance was assigned lower and upper distance bounds of 1.5 and 2.5 A, and the N-O distance assigned lower and upper distance bounds of 2.5 and 3.5 A.
###end p 18
###begin p 19
###xml 73 75 73 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref33">33</xref>
###xml 77 79 77 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref34">34</xref>
###xml 334 336 334 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref35">35</xref>
###xml 787 789 787 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref36">36</xref>
Structures were calculated using the Python interface of Xplor-NIH 2.18 (33, 34), using simulated annealing starting from random extended structures. Default values were used for all force constants and molecular parameters. Ensembles of NMR structures were analyzed for violated restraints using the VMD-Xplor visualization package (35). The structure determination was carried out iteratively whereby consistently violated restraints were reassigned, wherever possible, using existing structures or removed until a consistent set of constraints was obtained with few violations in the ensemble. The ensemble of structures was further refined with Xplor-NIH standard refinement protocols using the final set of restraints. The quality of the structures was assessed using PROCHECK-NMR (36).
###end p 19
###begin p 20
###xml 0 35 0 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Site-directed Mutagenesis of Sbi-IV</italic>
Site-directed Mutagenesis of Sbi-IV-Sbi-IV R231A and N238A single mutants and R231A-N238A double mutant were made using the QuikChange site-directed mutagenesis kit (Stratagene). The following oligonucleotide primers (MWG Biotech AG) were used to make the Sbi-IV R231A and N238A mutations: 5'-CAA TTG AAA ACA GAG CTT TAG CAC AAC GAG AAG-3' (forward primer), 5'-CTT CTC GTT GTG CTA AAG CTC TGT TTT CAA TTG-3' (reverse primer), 5'-GCA CAA CGA GAA GTT GCC AAA GCA CCT ATG GAT GTA AAA GAG-3' (forward primer), 5'-CTC TTT TAC ATC CAT AGG TGC TTT GGC AAC TTC TCG TTG TGC-3' (reverse primer). The mutant proteins were expressed and purified as described above for wild-type Sbi-IV.
###end p 20
###begin p 21
###xml 0 32 0 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Isothermal Titration Calorimetry</italic>
###xml 206 208 200 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref12">12</xref>
###xml 264 265 258 259 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 277 278 271 272 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 562 563 555 556 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 642 643 634 635 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 854 856 844 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref12">12</xref>
Isothermal Titration Calorimetry-Isothermal titration calorimetry experiments were done at 25 degreesC using a VP-ITC calorimeter (Microcal) in a very similar way to that described for Efb-C3 measurements (12). Sbi-IV, Sbi-III-IV, and C3dg were exchanged into 20 mm Tris, 150 mm NaCl, pH 8.0. For each interaction, reciprocal experiments were done, one with C3dg in the cell and Sbi-IV or Sbi-III-IV in the syringe and the other with Sbi-IV or Sbi-III-IV in the cell and C3dg in the syringe. The concentration of protein in the cell ranged between 10.4 and 19 mum, and the concentration of protein in the syringe ranged between 156 and 203 mum. A 1-mul injection of protein into the cell was followed by multiple injections of 5 mul at 4-min intervals, and the evolved heat was measured. All data were fit using Origin software (OriginLab) as described (12).
###end p 21
###begin p 22
###xml 0 29 0 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Serum Affinity Pulldown Assay</italic>
###xml 461 462 461 462 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 340 345 <span type="species:ncbi:9606">human</span>
Serum Affinity Pulldown Assay-Purified Sbi-I-II, Sbi-II, Sbi-III, Sbi-IV, Sbi-IV R231A, Sbi-IV N238A, and Sbi-IV R231A-N238A were each covalently coupled to a 1-ml NHS-activated Sepharose High Performance column (GE Healthcare) according to the manufacturer's instructions. After equilibration with phosphate-buffered saline (PBS), 5 ml of human serum (Cambrex) was applied to the column. Columns were washed with PBS, and bound proteins were eluted with a 0-1 m NaCl gradient over 10 ml. The binding of serum proteins was analyzed by SDS-PAGE. Size exclusion chromatography, with a Superdex-200 gel filtration column (GE Healthcare), was used for further purification of the bound fragments. Trypsinized protein fragments from excised gel slices were analyzed by MALDI-TOF. ProteinLynx software was used for protein identification.
###end p 22
###begin p 23
###xml 0 25 0 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Surface Plasmon Resonance</italic>
###xml 176 177 170 171 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 196 197 190 191 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 209 210 203 204 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 602 608 595 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6</xref>
###xml 771 772 764 765 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
Surface Plasmon Resonance-Surface plasmon resonance experiments were performed on a Biacore X (Biacore, Piscataway, NJ) instrument at 25 degreesC in HEPES-buffered saline (10 mm HEPES, pH 7.2, 3 mm EDTA, 150 mm NaCl, 0.005% (v/v) surfactant P-20 (Biacore)). 800 resonance units (RU) of C3dg were immobilized on a CM-5 sensor chip (Biacore) by standard amino coupling chemistry following the manufacturer's protocol, with a reference channel being sham-activated and deactivated. Wild-type or mutant Sbi-IV analytes were injected at a flow rate of 20 mul/min for 60 s at the concentrations indicated in Fig. 6, followed by a 60-s buffer flow before initiating the washing phase. The sensor chip was regenerated between successive analyte injections with a 60-s pulse of 2 m NaCl, which brought the sensorgram signal back to baseline.
###end p 23
###begin p 24
###xml 0 17 0 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Complement Assays</italic>
###xml 92 98 92 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al.</italic>
###xml 100 102 100 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref37">37</xref>
###xml 321 323 321 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref23">23</xref>
###xml 405 410 <span type="species:ncbi:9606">human</span>
###xml 626 631 <span type="species:ncbi:9606">human</span>
Complement Assays-The Wielisa Total Complement System Screen (Wieslab), described by Seelen et al. (37), was used to measure inhibition of the alternative complement pathway by a range of concentrations of Sbi-IV, Sbi-IV R231A, Sbi-IV N238A, and Sbi-IV R231-N238A, using a procedure similar to that described previously (23). Briefly, wild-type or mutant Sbi-IV was added to a particular concentration in human serum, and assayed for complement activity after 30 min of preincubation at 37 degreesC. The assay was completed in duplicate, according to the manufacturer's instructions, and included a blank, a positive control (human serum from healthy individuals), and a negative control (heat-inactivated serum). Inhibition of complement activation was quantified from absorbance at 405 nm using the calculation (sample - negative control)/(positive control - negative control) x 100%.
###end p 24
###begin title 25
RESULTS
###end title 25
###begin p 26
###xml 0 30 0 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sbi-IV Structure Determination</italic>
###xml 475 482 467 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="tbl1">Table 1</xref>
###xml 636 642 628 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1</xref>
###xml 877 879 869 871 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref36">36</xref>
###xml 1007 1014 999 1006 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="tbl1">Table 1</xref>
Sbi-IV Structure Determination-A semi-automated procedure for iterative NOE assignment was used to determine the structure of Sbi-IV. The final structures were generated using 1116 NOE-derived distance restraints (comprising 320 intraresidue, 621 sequential and medium range, and 175 long range NOEs where long range means between amino acids five or more apart in the sequence), 78 hydrogen bond restraints and 138 phi and Psi dihedral angle restraints (68 phi and 70 Psi) (Table 1). The ensemble of 20 simulated annealing structures selected from 50 calculations on the basis of lowest energy, and the average structure, are shown in Fig. 1. Over the regular secondary structure elements, the ensemble of structures has a backbone r.m.s.d. from the mean of 0.29 A and an r.m.s.d. of 0.93 A for all non-hydrogen atoms. A Ramachandran plot of the structures with PROCHECK-NMR (36) indicates that 100% of the residues (excluding Gly and Pro residues) lie in the most favored or additionally allowed regions (Table 1).
###end p 26
###begin p 27
###xml 0 7 0 7 <label xmlns:xlink="http://www.w3.org/1999/xlink">TABLE 1</label>
###xml 7 68 7 68 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Structural statistics on the NMR-derived structures of Sbi-IV</bold>
###xml 7 68 7 68 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="28"><bold>Structural statistics on the NMR-derived structures of Sbi-IV</bold></p>
###xml 7 68 7 68 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="28"><bold>Structural statistics on the NMR-derived structures of Sbi-IV</bold></p></caption>
###xml 68 100 68 100 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> Total number of NOE restraints </td>
###xml 100 100 100 100 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"/>
###xml 100 106 100 106 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 1116 </td>
###xml 68 106 68 106 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> Total number of NOE restraints </td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> 1116 </td></tr>
###xml 106 123 106 123 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> &#8194;&#8194;&#8194;Intraresidue </td>
###xml 123 123 123 123 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"/>
###xml 123 128 123 128 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 320 </td>
###xml 106 128 106 128 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> &#8194;&#8194;&#8194;Intraresidue </td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> 320 </td></tr>
###xml 155 156 155 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i</italic>
###xml 160 161 160 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i</italic>
###xml 128 171 128 171 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> &#8194;&#8194;&#8194;Sequential/med. range (<italic>i</italic> to <italic>i</italic> + 1 &#8211; 4) </td>
###xml 171 171 171 171 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"/>
###xml 171 176 171 176 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 621 </td>
###xml 128 176 128 176 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> &#8194;&#8194;&#8194;Sequential/med. range (<italic>i</italic> to <italic>i</italic> + 1 &#8211; 4) </td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> 621 </td></tr>
###xml 176 191 176 191 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> &#8194;&#8194;&#8194;Long range </td>
###xml 191 191 191 191 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"/>
###xml 191 196 191 196 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 175 </td>
###xml 176 196 176 196 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> &#8194;&#8194;&#8194;Long range </td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> 175 </td></tr>
###xml 196 233 196 233 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> Number of dihedral angle restraints </td>
###xml 233 233 233 233 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"/>
###xml 233 238 233 238 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 138 </td>
###xml 196 238 196 238 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> Number of dihedral angle restraints </td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> 138 </td></tr>
###xml 238 274 238 274 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> Number of hydrogen bond restraints </td>
###xml 274 274 274 274 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"/>
###xml 274 278 274 278 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 78 </td>
###xml 238 278 238 278 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> Number of hydrogen bond restraints </td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> 78 </td></tr>
###xml 306 307 306 307 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 306 307 306 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink"><sup>a</sup></italic>
###xml 306 307 306 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table-fn" rid="tblfn1"><italic><sup>a</sup></italic></xref>
###xml 278 307 278 307 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> R.m.s.d. for backbone atoms<xref ref-type="table-fn" rid="tblfn1"><italic><sup>a</sup></italic></xref></td>
###xml 307 307 307 307 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"/>
###xml 307 315 307 315 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 0.29 &#197; </td>
###xml 278 315 278 315 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> R.m.s.d. for backbone atoms<xref ref-type="table-fn" rid="tblfn1"><italic><sup>a</sup></italic></xref></td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> 0.29 &#197; </td></tr>
###xml 347 348 347 348 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 347 348 347 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink"><sup>a</sup></italic>
###xml 347 348 347 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table-fn" rid="tblfn1"><italic><sup>a</sup></italic></xref>
###xml 315 348 315 348 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> R.m.s.d. for non-hydrogen atoms<xref ref-type="table-fn" rid="tblfn1"><italic><sup>a</sup></italic></xref></td>
###xml 348 348 348 348 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"/>
###xml 348 356 348 356 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 0.93 &#197; </td>
###xml 315 356 315 356 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> R.m.s.d. for non-hydrogen atoms<xref ref-type="table-fn" rid="tblfn1"><italic><sup>a</sup></italic></xref></td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> 0.93 &#197; </td></tr>
###xml 68 356 68 356 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td colspan="1" rowspan="1" align="left" valign="top"> Total number of NOE restraints </td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> 1116 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> &#8194;&#8194;&#8194;Intraresidue </td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> 320 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> &#8194;&#8194;&#8194;Sequential/med. range (<italic>i</italic> to <italic>i</italic> + 1 &#8211; 4) </td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> 621 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> &#8194;&#8194;&#8194;Long range </td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> 175 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Number of dihedral angle restraints </td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> 138 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Number of hydrogen bond restraints </td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> 78 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> R.m.s.d. for backbone atoms<xref ref-type="table-fn" rid="tblfn1"><italic><sup>a</sup></italic></xref></td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> 0.29 &#197; </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> R.m.s.d. for non-hydrogen atoms<xref ref-type="table-fn" rid="tblfn1"><italic><sup>a</sup></italic></xref></td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> 0.93 &#197; </td></tr></tbody>
###xml 356 389 356 389 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Average numbers of NOE violations</bold>
###xml 356 389 356 389 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"><bold>Average numbers of NOE violations</bold></td>
###xml 389 389 389 389 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"/>
###xml 389 389 389 389 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"/>
###xml 356 389 356 389 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"><bold>Average numbers of NOE violations</bold></td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/></tr>
###xml 389 416 389 416 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> &#8194;&#8194;&#8194;&gt;0.5 &#197; (per structure) </td>
###xml 416 416 416 416 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"/>
###xml 416 421 416 421 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 1.5 </td>
###xml 389 421 389 421 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> &#8194;&#8194;&#8194;&gt;0.5 &#197; (per structure) </td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> 1.5 </td></tr>
###xml 356 421 356 421 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td colspan="1" rowspan="1" align="left" valign="top"><bold>Average numbers of NOE violations</bold></td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> &#8194;&#8194;&#8194;&gt;0.5 &#197; (per structure) </td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> 1.5 </td></tr></tbody>
###xml 421 464 421 464 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Average number of dihedral angle violations</bold>
###xml 421 464 421 464 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"><bold>Average number of dihedral angle violations</bold></td>
###xml 464 464 464 464 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"/>
###xml 464 464 464 464 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"/>
###xml 421 464 421 464 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"><bold>Average number of dihedral angle violations</bold></td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/></tr>
###xml 464 494 464 488 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> &#8194;&#8194;&#8194;&gt;5&#176; (per structure) </td>
###xml 494 494 488 488 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"/>
###xml 494 497 488 491 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 0 </td>
###xml 464 497 464 491 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> &#8194;&#8194;&#8194;&gt;5&#176; (per structure) </td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> 0 </td></tr>
###xml 421 497 421 491 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td colspan="1" rowspan="1" align="left" valign="top"><bold>Average number of dihedral angle violations</bold></td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> &#8194;&#8194;&#8194;&gt;5&#176; (per structure) </td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> 0 </td></tr></tbody>
###xml 497 497 491 491 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"/>
###xml 497 514 491 508 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Average structure</bold>
###xml 497 514 491 508 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><bold>Average structure</bold></td>
###xml 514 522 508 516 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Ensemble</bold>
###xml 514 522 508 516 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><bold>Ensemble</bold></td>
###xml 497 522 491 516 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"><bold>Average structure</bold></td><td colspan="1" rowspan="1" align="center" valign="top"><bold>Ensemble</bold></td></tr>
###xml 497 522 491 516 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td colspan="1" rowspan="1" align="left" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"><bold>Average structure</bold></td><td colspan="1" rowspan="1" align="center" valign="top"><bold>Ensemble</bold></td></tr></tbody>
###xml 522 547 516 541 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Ramachandran plot regions</bold>
###xml 547 548 541 542 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 547 548 541 542 <italic xmlns:xlink="http://www.w3.org/1999/xlink"><sup>b</sup></italic>
###xml 547 548 541 542 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic><sup>b</sup></italic></bold>
###xml 547 548 541 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table-fn" rid="tblfn2"><bold><italic><sup>b</sup></italic></bold></xref>
###xml 522 548 516 542 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"><bold>Ramachandran plot regions</bold><xref ref-type="table-fn" rid="tblfn2"><bold><italic><sup>b</sup></italic></bold></xref></td>
###xml 548 548 542 542 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"/>
###xml 548 548 542 542 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"/>
###xml 522 548 516 542 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"><bold>Ramachandran plot regions</bold><xref ref-type="table-fn" rid="tblfn2"><bold><italic><sup>b</sup></italic></bold></xref></td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/></tr>
###xml 548 569 542 563 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> &#8194;&#8194;&#8194;Most favored (%) </td>
###xml 569 575 563 569 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"> 88.4 </td>
###xml 575 581 569 575 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 92.4 </td>
###xml 548 581 542 575 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> &#8194;&#8194;&#8194;Most favored (%) </td><td colspan="1" rowspan="1" align="right" valign="top"> 88.4 </td><td colspan="1" rowspan="1" align="center" valign="top"> 92.4 </td></tr>
###xml 581 608 575 602 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> &#8194;&#8194;&#8194;Additional allowed (%) </td>
###xml 608 614 602 608 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"> 11.6 </td>
###xml 614 619 608 613 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 7.6 </td>
###xml 581 619 575 613 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> &#8194;&#8194;&#8194;Additional allowed (%) </td><td colspan="1" rowspan="1" align="right" valign="top"> 11.6 </td><td colspan="1" rowspan="1" align="center" valign="top"> 7.6 </td></tr>
###xml 619 646 613 640 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> &#8194;&#8194;&#8194;Generously allowed (%) </td>
###xml 646 651 640 645 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"> 0.0 </td>
###xml 651 656 645 650 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 0.0 </td>
###xml 619 656 613 650 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> &#8194;&#8194;&#8194;Generously allowed (%) </td><td colspan="1" rowspan="1" align="right" valign="top"> 0.0 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.0 </td></tr>
###xml 656 675 650 669 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> &#8194;&#8194;&#8194;Disallowed (%) </td>
###xml 675 680 669 674 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"> 0.0 </td>
###xml 680 685 674 679 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 0.0 </td>
###xml 656 685 650 679 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> &#8194;&#8194;&#8194;Disallowed (%) </td><td colspan="1" rowspan="1" align="right" valign="top"> 0.0 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.0 </td></tr>
###xml 522 685 516 679 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td colspan="1" rowspan="1" align="left" valign="top"><bold>Ramachandran plot regions</bold><xref ref-type="table-fn" rid="tblfn2"><bold><italic><sup>b</sup></italic></bold></xref></td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> &#8194;&#8194;&#8194;Most favored (%) </td><td colspan="1" rowspan="1" align="right" valign="top"> 88.4 </td><td colspan="1" rowspan="1" align="center" valign="top"> 92.4 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> &#8194;&#8194;&#8194;Additional allowed (%) </td><td colspan="1" rowspan="1" align="right" valign="top"> 11.6 </td><td colspan="1" rowspan="1" align="center" valign="top"> 7.6 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> &#8194;&#8194;&#8194;Generously allowed (%) </td><td colspan="1" rowspan="1" align="right" valign="top"> 0.0 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.0 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> &#8194;&#8194;&#8194;Disallowed (%) </td><td colspan="1" rowspan="1" align="right" valign="top"> 0.0 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.0 </td></tr></tbody>
###xml 68 685 68 679 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><tbody><tr><td colspan="1" rowspan="1" align="left" valign="top"> Total number of NOE restraints </td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> 1116 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> &#8194;&#8194;&#8194;Intraresidue </td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> 320 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> &#8194;&#8194;&#8194;Sequential/med. range (<italic>i</italic> to <italic>i</italic> + 1 &#8211; 4) </td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> 621 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> &#8194;&#8194;&#8194;Long range </td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> 175 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Number of dihedral angle restraints </td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> 138 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Number of hydrogen bond restraints </td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> 78 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> R.m.s.d. for backbone atoms<xref ref-type="table-fn" rid="tblfn1"><italic><sup>a</sup></italic></xref></td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> 0.29 &#197; </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> R.m.s.d. for non-hydrogen atoms<xref ref-type="table-fn" rid="tblfn1"><italic><sup>a</sup></italic></xref></td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> 0.93 &#197; </td></tr></tbody><tbody><tr><td colspan="1" rowspan="1" align="left" valign="top"><bold>Average numbers of NOE violations</bold></td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> &#8194;&#8194;&#8194;&gt;0.5 &#197; (per structure) </td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> 1.5 </td></tr></tbody><tbody><tr><td colspan="1" rowspan="1" align="left" valign="top"><bold>Average number of dihedral angle violations</bold></td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> &#8194;&#8194;&#8194;&gt;5&#176; (per structure) </td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> 0 </td></tr></tbody><tbody><tr><td colspan="1" rowspan="1" align="left" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"><bold>Average structure</bold></td><td colspan="1" rowspan="1" align="center" valign="top"><bold>Ensemble</bold></td></tr></tbody><tbody><tr><td colspan="1" rowspan="1" align="left" valign="top"><bold>Ramachandran plot regions</bold><xref ref-type="table-fn" rid="tblfn2"><bold><italic><sup>b</sup></italic></bold></xref></td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> &#8194;&#8194;&#8194;Most favored (%) </td><td colspan="1" rowspan="1" align="right" valign="top"> 88.4 </td><td colspan="1" rowspan="1" align="center" valign="top"> 92.4 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> &#8194;&#8194;&#8194;Additional allowed (%) </td><td colspan="1" rowspan="1" align="right" valign="top"> 11.6 </td><td colspan="1" rowspan="1" align="center" valign="top"> 7.6 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> &#8194;&#8194;&#8194;Generously allowed (%) </td><td colspan="1" rowspan="1" align="right" valign="top"> 0.0 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.0 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> &#8194;&#8194;&#8194;Disallowed (%) </td><td colspan="1" rowspan="1" align="right" valign="top"> 0.0 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.0 </td></tr></tbody></table>
###xml 685 686 679 680 <label xmlns:xlink="http://www.w3.org/1999/xlink">a</label>
###xml 686 777 680 771 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="29">The r.m.s.d. from the mean structure calculated over residues 201&#8211;222, 228&#8211;238, and 245&#8211;261</p>
###xml 685 777 679 771 <fn xmlns:xlink="http://www.w3.org/1999/xlink" id="tblfn1"><label>a</label><p textid="29">The r.m.s.d. from the mean structure calculated over residues 201&#8211;222, 228&#8211;238, and 245&#8211;261</p></fn>
###xml 777 778 771 772 <label xmlns:xlink="http://www.w3.org/1999/xlink">b</label>
###xml 808 810 802 804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref36">36</xref>
###xml 778 811 772 805 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="30">Calculated with PROCHECK-NMR (<xref ref-type="bibr" rid="ref36">36</xref>)</p>
###xml 777 811 771 805 <fn xmlns:xlink="http://www.w3.org/1999/xlink" id="tblfn2"><label>b</label><p textid="30">Calculated with PROCHECK-NMR (<xref ref-type="bibr" rid="ref36">36</xref>)</p></fn>
###xml 685 811 679 805 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><fn id="tblfn1"><label>a</label><p textid="29">The r.m.s.d. from the mean structure calculated over residues 201&#8211;222, 228&#8211;238, and 245&#8211;261</p></fn><fn id="tblfn2"><label>b</label><p textid="30">Calculated with PROCHECK-NMR (<xref ref-type="bibr" rid="ref36">36</xref>)</p></fn></table-wrap-foot>
###xml 0 811 0 805 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="tbl1"><label>TABLE 1</label><caption><p textid="28"><bold>Structural statistics on the NMR-derived structures of Sbi-IV</bold></p></caption><table frame="hsides" rules="groups"><tbody><tr><td colspan="1" rowspan="1" align="left" valign="top"> Total number of NOE restraints </td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> 1116 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> &#8194;&#8194;&#8194;Intraresidue </td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> 320 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> &#8194;&#8194;&#8194;Sequential/med. range (<italic>i</italic> to <italic>i</italic> + 1 &#8211; 4) </td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> 621 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> &#8194;&#8194;&#8194;Long range </td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> 175 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Number of dihedral angle restraints </td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> 138 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Number of hydrogen bond restraints </td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> 78 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> R.m.s.d. for backbone atoms<xref ref-type="table-fn" rid="tblfn1"><italic><sup>a</sup></italic></xref></td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> 0.29 &#197; </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> R.m.s.d. for non-hydrogen atoms<xref ref-type="table-fn" rid="tblfn1"><italic><sup>a</sup></italic></xref></td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> 0.93 &#197; </td></tr></tbody><tbody><tr><td colspan="1" rowspan="1" align="left" valign="top"><bold>Average numbers of NOE violations</bold></td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> &#8194;&#8194;&#8194;&gt;0.5 &#197; (per structure) </td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> 1.5 </td></tr></tbody><tbody><tr><td colspan="1" rowspan="1" align="left" valign="top"><bold>Average number of dihedral angle violations</bold></td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> &#8194;&#8194;&#8194;&gt;5&#176; (per structure) </td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> 0 </td></tr></tbody><tbody><tr><td colspan="1" rowspan="1" align="left" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"><bold>Average structure</bold></td><td colspan="1" rowspan="1" align="center" valign="top"><bold>Ensemble</bold></td></tr></tbody><tbody><tr><td colspan="1" rowspan="1" align="left" valign="top"><bold>Ramachandran plot regions</bold><xref ref-type="table-fn" rid="tblfn2"><bold><italic><sup>b</sup></italic></bold></xref></td><td colspan="1" rowspan="1" align="right" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> &#8194;&#8194;&#8194;Most favored (%) </td><td colspan="1" rowspan="1" align="right" valign="top"> 88.4 </td><td colspan="1" rowspan="1" align="center" valign="top"> 92.4 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> &#8194;&#8194;&#8194;Additional allowed (%) </td><td colspan="1" rowspan="1" align="right" valign="top"> 11.6 </td><td colspan="1" rowspan="1" align="center" valign="top"> 7.6 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> &#8194;&#8194;&#8194;Generously allowed (%) </td><td colspan="1" rowspan="1" align="right" valign="top"> 0.0 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.0 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> &#8194;&#8194;&#8194;Disallowed (%) </td><td colspan="1" rowspan="1" align="right" valign="top"> 0.0 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.0 </td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><label>a</label><p textid="29">The r.m.s.d. from the mean structure calculated over residues 201&#8211;222, 228&#8211;238, and 245&#8211;261</p></fn><fn id="tblfn2"><label>b</label><p textid="30">Calculated with PROCHECK-NMR (<xref ref-type="bibr" rid="ref36">36</xref>)</p></fn></table-wrap-foot></table-wrap>
TABLE 1Structural statistics on the NMR-derived structures of Sbi-IV Total number of NOE restraints  1116     Intraresidue  320     Sequential/med. range (i to i + 1 - 4)  621     Long range  175  Number of dihedral angle restraints  138  Number of hydrogen bond restraints  78  R.m.s.d. for backbone atomsa 0.29 A  R.m.s.d. for non-hydrogen atomsa 0.93 A Average numbers of NOE violations    >0.5 A (per structure)  1.5 Average number of dihedral angle violations    >5degrees (per structure)  0 Average structureEnsembleRamachandran plot regionsb    Most favored (%)  88.4  92.4     Additional allowed (%)  11.6  7.6     Generously allowed (%)  0.0  0.0     Disallowed (%)  0.0  0.0 aThe r.m.s.d. from the mean structure calculated over residues 201-222, 228-238, and 245-261bCalculated with PROCHECK-NMR (36)
###end p 27
###begin p 28
###xml 0 61 0 61 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Structural statistics on the NMR-derived structures of Sbi-IV</bold>
Structural statistics on the NMR-derived structures of Sbi-IV
###end p 28
###begin p 29
The r.m.s.d. from the mean structure calculated over residues 201-222, 228-238, and 245-261
###end p 29
###begin p 30
###xml 30 32 30 32 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref36">36</xref>
Calculated with PROCHECK-NMR (36)
###end p 30
###begin p 31
###xml 0 33 0 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sbi-IV Forms a Three-Helix Bundle</italic>
###xml 75 81 75 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1</xref>
###xml 744 753 732 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus</italic>
###xml 792 794 780 782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref12">12</xref>
###xml 802 804 790 792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref13">13</xref>
###xml 813 815 801 803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref25">25</xref>
###xml 827 829 815 817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref26">26</xref>
###xml 832 838 820 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 744 753 <span type="species:ncbi:1280">S. aureus</span>
Sbi-IV Forms a Three-Helix Bundle-Sbi-IV adopts a three-helix bundle fold (Fig. 1) with approximate overall dimensions of 45 A x 25 A x 25 A. Helix alpha1 (residues Glu-201 to Asn-222) is connected by a loop to helix alpha2 (residues Glu-228 to Asn-238), which is connected by a loop to helix alpha3 (residues Lys-245 to Ala-261). The N-terminal six residues and C-terminal three residues are disordered. None of the residues 198-206 and 257-266 is involved in long range NOEs, and these residues make essentially no contribution to the tertiary structure of the domain. The core of the bundle comprises hydrophobic residues with hydrophilic side chains oriented toward solvent. A similar three-helix bundle fold has been observed in the other S. aureus complement modulatory proteins Efb-C (12), Ehp (13), SCIN (25), and SpA (26) (Fig. 2).
###end p 31
###begin p 32
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 1.</label>
###xml 9 29 9 29 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Structure of Sbi-IV.</bold>
###xml 29 30 29 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 46 51 46 47 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#945;</sup>
###xml 130 134 126 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">blue</italic>
###xml 156 159 152 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 179 196 175 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B, ribbon diagram</italic>
###xml 236 237 232 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 9 328 9 320 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="33"><bold>Structure of Sbi-IV.</bold><italic>A</italic>, backbone (N, C<sup>&#945;</sup>, and C&#8242;) trace of the 20 lowest energy structures colored as a continuum from <italic>blue</italic> at the N terminus to <italic>red</italic> at the C terminus. <italic>B, ribbon diagram</italic> of the average structure colored as in <italic>A</italic>. The &#945;-helices and N and C termini are labeled. This figure was generated using PyMol.</p>
###xml 9 328 9 320 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="33"><bold>Structure of Sbi-IV.</bold><italic>A</italic>, backbone (N, C<sup>&#945;</sup>, and C&#8242;) trace of the 20 lowest energy structures colored as a continuum from <italic>blue</italic> at the N terminus to <italic>red</italic> at the C terminus. <italic>B, ribbon diagram</italic> of the average structure colored as in <italic>A</italic>. The &#945;-helices and N and C termini are labeled. This figure was generated using PyMol.</p></caption>
###xml 328 328 320 320 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0350846530001"/>
###xml 0 328 0 320 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig1"><label>FIGURE 1.</label><caption><p textid="33"><bold>Structure of Sbi-IV.</bold><italic>A</italic>, backbone (N, C<sup>&#945;</sup>, and C&#8242;) trace of the 20 lowest energy structures colored as a continuum from <italic>blue</italic> at the N terminus to <italic>red</italic> at the C terminus. <italic>B, ribbon diagram</italic> of the average structure colored as in <italic>A</italic>. The &#945;-helices and N and C termini are labeled. This figure was generated using PyMol.</p></caption><graphic xlink:href="zbc0350846530001"/></fig>
FIGURE 1.Structure of Sbi-IV.A, backbone (N, Calpha, and C') trace of the 20 lowest energy structures colored as a continuum from blue at the N terminus to red at the C terminus. B, ribbon diagram of the average structure colored as in A. The alpha-helices and N and C termini are labeled. This figure was generated using PyMol.
###end p 32
###begin p 33
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Structure of Sbi-IV.</bold>
###xml 20 21 20 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 37 42 37 38 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#945;</sup>
###xml 121 125 117 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">blue</italic>
###xml 147 150 143 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 170 187 166 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B, ribbon diagram</italic>
###xml 227 228 223 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
Structure of Sbi-IV.A, backbone (N, Calpha, and C') trace of the 20 lowest energy structures colored as a continuum from blue at the N terminus to red at the C terminus. B, ribbon diagram of the average structure colored as in A. The alpha-helices and N and C termini are labeled. This figure was generated using PyMol.
###end p 33
###begin p 34
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 2.</label>
###xml 34 43 34 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus</italic>
###xml 9 70 9 70 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Structural comparison of <italic>S. aureus</italic> immune modulator proteins.</bold>
###xml 193 199 193 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ribbon</italic>
###xml 204 222 204 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">schematic topology</italic>
###xml 256 260 252 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">blue</italic>
###xml 272 278 264 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">yellow</italic>
###xml 294 297 282 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 9 337 9 325 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="35"><bold>Structural comparison of <italic>S. aureus</italic> immune modulator proteins.</bold> Sbi-IV (PDB code 2jvh), Efb-C (PDB 2gom), Ehp (PDB 2noj), SCIN (PDB 2qff), and protein A domain B (PDB 1ss1) are shown in <italic>ribbon</italic> and <italic>schematic topology</italic> representations. Helix &#945;1 is <italic>blue</italic>, &#945;2 is <italic>yellow</italic>, and &#945;3 is <italic>red</italic>. This figure was generated using PyMol.</p>
###xml 9 337 9 325 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="35"><bold>Structural comparison of <italic>S. aureus</italic> immune modulator proteins.</bold> Sbi-IV (PDB code 2jvh), Efb-C (PDB 2gom), Ehp (PDB 2noj), SCIN (PDB 2qff), and protein A domain B (PDB 1ss1) are shown in <italic>ribbon</italic> and <italic>schematic topology</italic> representations. Helix &#945;1 is <italic>blue</italic>, &#945;2 is <italic>yellow</italic>, and &#945;3 is <italic>red</italic>. This figure was generated using PyMol.</p></caption>
###xml 337 337 325 325 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0350846530002"/>
###xml 0 337 0 325 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig2"><label>FIGURE 2.</label><caption><p textid="35"><bold>Structural comparison of <italic>S. aureus</italic> immune modulator proteins.</bold> Sbi-IV (PDB code 2jvh), Efb-C (PDB 2gom), Ehp (PDB 2noj), SCIN (PDB 2qff), and protein A domain B (PDB 1ss1) are shown in <italic>ribbon</italic> and <italic>schematic topology</italic> representations. Helix &#945;1 is <italic>blue</italic>, &#945;2 is <italic>yellow</italic>, and &#945;3 is <italic>red</italic>. This figure was generated using PyMol.</p></caption><graphic xlink:href="zbc0350846530002"/></fig>
###xml 34 43 <span type="species:ncbi:1280">S. aureus</span>
FIGURE 2.Structural comparison of S. aureus immune modulator proteins. Sbi-IV (PDB code 2jvh), Efb-C (PDB 2gom), Ehp (PDB 2noj), SCIN (PDB 2qff), and protein A domain B (PDB 1ss1) are shown in ribbon and schematic topology representations. Helix alpha1 is blue, alpha2 is yellow, and alpha3 is red. This figure was generated using PyMol.
###end p 34
###begin p 35
###xml 25 34 25 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus</italic>
###xml 0 61 0 61 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Structural comparison of <italic>S. aureus</italic> immune modulator proteins.</bold>
###xml 184 190 184 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ribbon</italic>
###xml 195 213 195 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">schematic topology</italic>
###xml 247 251 243 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">blue</italic>
###xml 263 269 255 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">yellow</italic>
###xml 285 288 273 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 25 34 <span type="species:ncbi:1280">S. aureus</span>
Structural comparison of S. aureus immune modulator proteins. Sbi-IV (PDB code 2jvh), Efb-C (PDB 2gom), Ehp (PDB 2noj), SCIN (PDB 2qff), and protein A domain B (PDB 1ss1) are shown in ribbon and schematic topology representations. Helix alpha1 is blue, alpha2 is yellow, and alpha3 is red. This figure was generated using PyMol.
###end p 35
###begin p 36
###xml 0 28 0 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Isolated Sbi-III Is Unfolded</italic>
###xml 33 34 33 34 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 36 38 36 38 <sup xmlns:xlink="http://www.w3.org/1999/xlink">15</sup>
###xml 431 432 431 432 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 607 611 607 611 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.e.</italic>
###xml 667 668 667 668 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 670 672 670 672 <sup xmlns:xlink="http://www.w3.org/1999/xlink">15</sup>
Isolated Sbi-III Is Unfolded-The 1H-15N HSQC spectrum of Sbi-III contains 52 backbone NH peaks (supplemental Fig. S1). This compares with 56 peaks expected based on the amino acid sequence of the construct including the three N-terminal residues, GAM, from the expression vector. This almost exact 1:1 correspondence with the expected number of peaks indicates that Sbi-III adopts a single conformation in solution, but the narrow 1H chemical shift dispersion, with every backbone NH peak except three located in the range 8.0-8.5 ppm, indicates that this conformation lacks significant tertiary structure, i.e. Sbi-III is natively unfolded. The peak patterns in the 1H-15N HSQC spectra of Sbi-IV (supplemental Fig. S2) and Sbi-III-IV (supplemental Fig. S3) indicate that Sbi-III remains unfolded in the presence of Sbi-IV. We cannot preclude, however, the possibility that Sbi-III adopts a different conformation in full-length Sbi where its conformation may be influenced by one or more of the other domains.
###end p 36
###begin p 37
###xml 0 54 0 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sbi-IV and Sbi-III-IV Bind C3dg with 1:1 Stoichiometry</italic>
###xml 244 250 244 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3</xref>
###xml 255 262 255 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="tbl2">Table 2</xref>
###xml 379 380 379 380 <sub xmlns:xlink="http://www.w3.org/1999/xlink">d</sub>
###xml 378 380 378 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K<sub>d</sub></italic>
###xml 398 399 397 398 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 411 412 409 410 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 591 593 589 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref12">12</xref>
###xml 604 606 602 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref13">13</xref>
Sbi-IV and Sbi-III-IV Bind C3dg with 1:1 Stoichiometry-Thermodynamics of the interactions between Sbi-IV and C3dg and between Sbi-III-IV and C3dg were measured by reciprocal (Sbi:C3dg and C3dg:Sbi) isothermal titration calorimetry experiments (Fig. 3 and Table 2). The ITC results indicate that the stoichiometry of both Sbi-IV:C3dg and Sbi-III-IV:C3dg interactions is 1:1 with Kd values of 0.35 mum and 0.28 mum (averages of results from reciprocal ITC titrations). These affinities are lower than the nanomolar to subnanomolar C3dg affinities previously measured by SPR and ITC for Efb-C (12) and Ehp (13).
###end p 37
###begin p 38
###xml 0 7 0 7 <label xmlns:xlink="http://www.w3.org/1999/xlink">TABLE 2</label>
###xml 7 94 7 94 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Assessment of C3dg binding to Sbi-III-IV and Sbi-IV by isothermal titration calorimetry</bold>
###xml 7 94 7 94 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="39"><bold>Assessment of C3dg binding to Sbi-III-IV and Sbi-IV by isothermal titration calorimetry</bold></p>
###xml 7 94 7 94 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="39"><bold>Assessment of C3dg binding to Sbi-III-IV and Sbi-IV by isothermal titration calorimetry</bold></p></caption>
###xml 94 101 94 101 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Titrant</bold>
###xml 94 101 94 101 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><bold>Titrant</bold></th>
###xml 101 105 101 105 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Cell</bold>
###xml 101 105 101 105 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><bold>Cell</bold></th>
###xml 105 106 105 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 105 106 105 106 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>n</italic></bold>
###xml 106 107 106 107 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 106 107 106 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink"><sup>a</sup></italic>
###xml 106 107 106 107 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic><sup>a</sup></italic></bold>
###xml 106 107 106 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table-fn" rid="tblfn3"><bold><italic><sup>a</sup></italic></bold></xref>
###xml 105 107 105 107 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><bold><italic>n</italic></bold><xref ref-type="table-fn" rid="tblfn3"><bold><italic><sup>a</sup></italic></bold></xref></th>
###xml 108 109 108 109 <sub xmlns:xlink="http://www.w3.org/1999/xlink">d</sub>
###xml 107 109 107 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K<sub>d</sub></italic>
###xml 107 109 107 109 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>K<sub>d</sub></italic></bold>
###xml 107 109 107 109 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><bold><italic>K<sub>d</sub></italic></bold></th>
###xml 114 115 110 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 109 115 109 111 <bold xmlns:xlink="http://www.w3.org/1999/xlink">&#916;<italic>H</italic></bold>
###xml 109 115 109 111 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><bold>&#916;<italic>H</italic></bold></th>
###xml 120 121 112 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 115 121 111 113 <bold xmlns:xlink="http://www.w3.org/1999/xlink">&#916;<italic>S</italic></bold>
###xml 115 121 111 113 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><bold>&#916;<italic>S</italic></bold></th>
###xml 94 121 94 113 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th colspan="1" rowspan="1" align="center" valign="top"><bold>Titrant</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Cell</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>n</italic></bold><xref ref-type="table-fn" rid="tblfn3"><bold><italic><sup>a</sup></italic></bold></xref></th><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>K<sub>d</sub></italic></bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>&#916;<italic>H</italic></bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>&#916;<italic>S</italic></bold></th></tr>
###xml 94 121 94 113 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th colspan="1" rowspan="1" align="center" valign="top"><bold>Titrant</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Cell</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>n</italic></bold><xref ref-type="table-fn" rid="tblfn3"><bold><italic><sup>a</sup></italic></bold></xref></th><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>K<sub>d</sub></italic></bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>&#916;<italic>H</italic></bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>&#916;<italic>S</italic></bold></th></tr></thead>
###xml 121 121 113 113 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"/>
###xml 121 121 113 113 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"/>
###xml 121 121 113 113 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"/>
###xml 124 125 115 116 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 124 125 115 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink"><sc>m</sc></italic>
###xml 121 125 113 116 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> &#956;<italic><sc>m</sc></italic></td>
###xml 125 133 116 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">kcal/mol</italic>
###xml 125 133 116 124 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><italic>kcal/mol</italic></td>
###xml 133 142 124 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cal/mol/K</italic>
###xml 133 142 124 133 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><italic>cal/mol/K</italic></td>
###xml 121 142 113 133 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> &#956;<italic><sc>m</sc></italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>kcal/mol</italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>cal/mol/K</italic></td></tr>
###xml 142 154 133 145 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> Sbi-III-IV </td>
###xml 154 160 145 151 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> C3dg </td>
###xml 160 166 151 157 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 1.04 </td>
###xml 166 172 157 163 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 0.40 </td>
###xml 172 178 163 169 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> &#8211;4.6 </td>
###xml 178 184 169 175 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 13.9 </td>
###xml 142 184 133 175 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> Sbi-III-IV </td><td colspan="1" rowspan="1" align="center" valign="top"> C3dg </td><td colspan="1" rowspan="1" align="center" valign="top"> 1.04 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.40 </td><td colspan="1" rowspan="1" align="center" valign="top"> &#8211;4.6 </td><td colspan="1" rowspan="1" align="center" valign="top"> 13.9 </td></tr>
###xml 184 192 175 183 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> Sbi-IV </td>
###xml 192 198 183 189 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> C3dg </td>
###xml 198 204 189 195 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 1.15 </td>
###xml 204 210 195 201 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 0.36 </td>
###xml 210 216 201 207 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> &#8211;3.8 </td>
###xml 216 222 207 213 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 16.7 </td>
###xml 184 222 175 213 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> Sbi-IV </td><td colspan="1" rowspan="1" align="center" valign="top"> C3dg </td><td colspan="1" rowspan="1" align="center" valign="top"> 1.15 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.36 </td><td colspan="1" rowspan="1" align="center" valign="top"> &#8211;3.8 </td><td colspan="1" rowspan="1" align="center" valign="top"> 16.7 </td></tr>
###xml 222 228 213 219 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> C3dg </td>
###xml 228 240 219 231 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> Sbi-III-IV </td>
###xml 240 246 231 237 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 0.92 </td>
###xml 246 252 237 243 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 0.17 </td>
###xml 252 258 243 249 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> &#8211;3.9 </td>
###xml 258 264 249 255 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 17.8 </td>
###xml 222 264 213 255 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> C3dg </td><td colspan="1" rowspan="1" align="center" valign="top"> Sbi-III-IV </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.92 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.17 </td><td colspan="1" rowspan="1" align="center" valign="top"> &#8211;3.9 </td><td colspan="1" rowspan="1" align="center" valign="top"> 17.8 </td></tr>
###xml 264 270 255 261 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> C3dg </td>
###xml 270 278 261 269 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> Sbi-IV </td>
###xml 278 284 269 275 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 0.93 </td>
###xml 284 290 275 281 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 0.34 </td>
###xml 290 296 281 287 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> &#8211;4.6 </td>
###xml 296 302 287 293 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 14.0 </td>
###xml 264 302 255 293 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> C3dg </td><td colspan="1" rowspan="1" align="center" valign="top"> Sbi-IV </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.93 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.34 </td><td colspan="1" rowspan="1" align="center" valign="top"> &#8211;4.6 </td><td colspan="1" rowspan="1" align="center" valign="top"> 14.0 </td></tr>
###xml 121 302 113 293 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td colspan="1" rowspan="1" align="left" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> &#956;<italic><sc>m</sc></italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>kcal/mol</italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>cal/mol/K</italic></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Sbi-III-IV </td><td colspan="1" rowspan="1" align="center" valign="top"> C3dg </td><td colspan="1" rowspan="1" align="center" valign="top"> 1.04 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.40 </td><td colspan="1" rowspan="1" align="center" valign="top"> &#8211;4.6 </td><td colspan="1" rowspan="1" align="center" valign="top"> 13.9 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Sbi-IV </td><td colspan="1" rowspan="1" align="center" valign="top"> C3dg </td><td colspan="1" rowspan="1" align="center" valign="top"> 1.15 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.36 </td><td colspan="1" rowspan="1" align="center" valign="top"> &#8211;3.8 </td><td colspan="1" rowspan="1" align="center" valign="top"> 16.7 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> C3dg </td><td colspan="1" rowspan="1" align="center" valign="top"> Sbi-III-IV </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.92 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.17 </td><td colspan="1" rowspan="1" align="center" valign="top"> &#8211;3.9 </td><td colspan="1" rowspan="1" align="center" valign="top"> 17.8 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> C3dg </td><td colspan="1" rowspan="1" align="center" valign="top"> Sbi-IV </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.93 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.34 </td><td colspan="1" rowspan="1" align="center" valign="top"> &#8211;4.6 </td><td colspan="1" rowspan="1" align="center" valign="top"> 14.0 </td></tr></tbody>
###xml 94 302 94 293 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1" align="center" valign="top"><bold>Titrant</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Cell</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>n</italic></bold><xref ref-type="table-fn" rid="tblfn3"><bold><italic><sup>a</sup></italic></bold></xref></th><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>K<sub>d</sub></italic></bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>&#916;<italic>H</italic></bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>&#916;<italic>S</italic></bold></th></tr></thead><tbody><tr><td colspan="1" rowspan="1" align="left" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> &#956;<italic><sc>m</sc></italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>kcal/mol</italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>cal/mol/K</italic></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Sbi-III-IV </td><td colspan="1" rowspan="1" align="center" valign="top"> C3dg </td><td colspan="1" rowspan="1" align="center" valign="top"> 1.04 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.40 </td><td colspan="1" rowspan="1" align="center" valign="top"> &#8211;4.6 </td><td colspan="1" rowspan="1" align="center" valign="top"> 13.9 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Sbi-IV </td><td colspan="1" rowspan="1" align="center" valign="top"> C3dg </td><td colspan="1" rowspan="1" align="center" valign="top"> 1.15 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.36 </td><td colspan="1" rowspan="1" align="center" valign="top"> &#8211;3.8 </td><td colspan="1" rowspan="1" align="center" valign="top"> 16.7 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> C3dg </td><td colspan="1" rowspan="1" align="center" valign="top"> Sbi-III-IV </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.92 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.17 </td><td colspan="1" rowspan="1" align="center" valign="top"> &#8211;3.9 </td><td colspan="1" rowspan="1" align="center" valign="top"> 17.8 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> C3dg </td><td colspan="1" rowspan="1" align="center" valign="top"> Sbi-IV </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.93 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.34 </td><td colspan="1" rowspan="1" align="center" valign="top"> &#8211;4.6 </td><td colspan="1" rowspan="1" align="center" valign="top"> 14.0 </td></tr></tbody></table>
###xml 302 303 293 294 <label xmlns:xlink="http://www.w3.org/1999/xlink">a</label>
###xml 303 305 294 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n,</italic>
###xml 303 387 294 378 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="40"><italic>n,</italic> molar ratio of titrant molecule bound to ligand molecule in the cell at satration</p>
###xml 302 387 293 378 <fn xmlns:xlink="http://www.w3.org/1999/xlink" id="tblfn3"><label>a</label><p textid="40"><italic>n,</italic> molar ratio of titrant molecule bound to ligand molecule in the cell at satration</p></fn>
###xml 302 387 293 378 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><fn id="tblfn3"><label>a</label><p textid="40"><italic>n,</italic> molar ratio of titrant molecule bound to ligand molecule in the cell at satration</p></fn></table-wrap-foot>
###xml 0 387 0 378 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="tbl2"><label>TABLE 2</label><caption><p textid="39"><bold>Assessment of C3dg binding to Sbi-III-IV and Sbi-IV by isothermal titration calorimetry</bold></p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1" align="center" valign="top"><bold>Titrant</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Cell</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>n</italic></bold><xref ref-type="table-fn" rid="tblfn3"><bold><italic><sup>a</sup></italic></bold></xref></th><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>K<sub>d</sub></italic></bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>&#916;<italic>H</italic></bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>&#916;<italic>S</italic></bold></th></tr></thead><tbody><tr><td colspan="1" rowspan="1" align="left" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> &#956;<italic><sc>m</sc></italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>kcal/mol</italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>cal/mol/K</italic></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Sbi-III-IV </td><td colspan="1" rowspan="1" align="center" valign="top"> C3dg </td><td colspan="1" rowspan="1" align="center" valign="top"> 1.04 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.40 </td><td colspan="1" rowspan="1" align="center" valign="top"> &#8211;4.6 </td><td colspan="1" rowspan="1" align="center" valign="top"> 13.9 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Sbi-IV </td><td colspan="1" rowspan="1" align="center" valign="top"> C3dg </td><td colspan="1" rowspan="1" align="center" valign="top"> 1.15 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.36 </td><td colspan="1" rowspan="1" align="center" valign="top"> &#8211;3.8 </td><td colspan="1" rowspan="1" align="center" valign="top"> 16.7 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> C3dg </td><td colspan="1" rowspan="1" align="center" valign="top"> Sbi-III-IV </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.92 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.17 </td><td colspan="1" rowspan="1" align="center" valign="top"> &#8211;3.9 </td><td colspan="1" rowspan="1" align="center" valign="top"> 17.8 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> C3dg </td><td colspan="1" rowspan="1" align="center" valign="top"> Sbi-IV </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.93 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.34 </td><td colspan="1" rowspan="1" align="center" valign="top"> &#8211;4.6 </td><td colspan="1" rowspan="1" align="center" valign="top"> 14.0 </td></tr></tbody></table><table-wrap-foot><fn id="tblfn3"><label>a</label><p textid="40"><italic>n,</italic> molar ratio of titrant molecule bound to ligand molecule in the cell at satration</p></fn></table-wrap-foot></table-wrap>
TABLE 2Assessment of C3dg binding to Sbi-III-IV and Sbi-IV by isothermal titration calorimetryTitrantCellnaKdDeltaHDeltaS mumkcal/molcal/mol/K Sbi-III-IV  C3dg  1.04  0.40  -4.6  13.9  Sbi-IV  C3dg  1.15  0.36  -3.8  16.7  C3dg  Sbi-III-IV  0.92  0.17  -3.9  17.8  C3dg  Sbi-IV  0.93  0.34  -4.6  14.0 an, molar ratio of titrant molecule bound to ligand molecule in the cell at satration
###end p 38
###begin p 39
###xml 0 87 0 87 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Assessment of C3dg binding to Sbi-III-IV and Sbi-IV by isothermal titration calorimetry</bold>
Assessment of C3dg binding to Sbi-III-IV and Sbi-IV by isothermal titration calorimetry
###end p 39
###begin p 40
###xml 0 2 0 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n,</italic>
n, molar ratio of titrant molecule bound to ligand molecule in the cell at satration
###end p 40
###begin p 41
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 3.</label>
###xml 71 72 71 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 95 96 95 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 9 111 9 111 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Isothermal titration calorimetry analyses of the Sbi-IV:C3dg (<italic>A</italic>) and Sbi-III-IV:C3dg (<italic>B</italic>) interactions.</bold>
###xml 115 116 115 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 167 168 166 167 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 241 242 239 240 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 247 248 245 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 299 300 296 297 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 377 378 373 374 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 505 506 501 502 <sub xmlns:xlink="http://www.w3.org/1999/xlink">d</sub>
###xml 504 506 500 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K<sub>d</sub></italic>
###xml 517 518 509 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 582 587 574 579 <italic xmlns:xlink="http://www.w3.org/1999/xlink">inset</italic>
###xml 608 609 596 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 805 812 793 800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="tbl2">Table 2</xref>
###xml 9 814 9 802 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="42"><bold>Isothermal titration calorimetry analyses of the Sbi-IV:C3dg (<italic>A</italic>) and Sbi-III-IV:C3dg (<italic>B</italic>) interactions.</bold> In <italic>A</italic>, the concentration of C3dg in the cell was 10.4 &#956;<sc>m</sc>, and the concentration of the Sbi-IV injectant in the syringe was 203 &#956;<sc>m</sc>. In <italic>B</italic>, the concentration of C3dg in the cell was 12.0 &#956;<sc>m</sc>, and the concentration of the Sbi-III-IV injectant in the syringe was 173 &#956;<sc>m</sc>. In each case, the data were fit to a single class of binding site model, and the best fit parameters for N (stoichiometry), <italic>K<sub>d</sub></italic>, and &#916;<italic>H</italic>, along with the error estimates of the fit, are provided as an <italic>inset</italic> to each panel. &#916;<italic>S</italic> is a secondarily calculated value, and thus there is no error estimate. The reciprocal experiments in which C3dg was titrated into Sbi-IV or Sbi-III-IV were also performed (results summarized in <xref ref-type="table" rid="tbl2">Table 2</xref>).</p>
###xml 9 814 9 802 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="42"><bold>Isothermal titration calorimetry analyses of the Sbi-IV:C3dg (<italic>A</italic>) and Sbi-III-IV:C3dg (<italic>B</italic>) interactions.</bold> In <italic>A</italic>, the concentration of C3dg in the cell was 10.4 &#956;<sc>m</sc>, and the concentration of the Sbi-IV injectant in the syringe was 203 &#956;<sc>m</sc>. In <italic>B</italic>, the concentration of C3dg in the cell was 12.0 &#956;<sc>m</sc>, and the concentration of the Sbi-III-IV injectant in the syringe was 173 &#956;<sc>m</sc>. In each case, the data were fit to a single class of binding site model, and the best fit parameters for N (stoichiometry), <italic>K<sub>d</sub></italic>, and &#916;<italic>H</italic>, along with the error estimates of the fit, are provided as an <italic>inset</italic> to each panel. &#916;<italic>S</italic> is a secondarily calculated value, and thus there is no error estimate. The reciprocal experiments in which C3dg was titrated into Sbi-IV or Sbi-III-IV were also performed (results summarized in <xref ref-type="table" rid="tbl2">Table 2</xref>).</p></caption>
###xml 814 814 802 802 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0350846530003"/>
###xml 0 814 0 802 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig3"><label>FIGURE 3.</label><caption><p textid="42"><bold>Isothermal titration calorimetry analyses of the Sbi-IV:C3dg (<italic>A</italic>) and Sbi-III-IV:C3dg (<italic>B</italic>) interactions.</bold> In <italic>A</italic>, the concentration of C3dg in the cell was 10.4 &#956;<sc>m</sc>, and the concentration of the Sbi-IV injectant in the syringe was 203 &#956;<sc>m</sc>. In <italic>B</italic>, the concentration of C3dg in the cell was 12.0 &#956;<sc>m</sc>, and the concentration of the Sbi-III-IV injectant in the syringe was 173 &#956;<sc>m</sc>. In each case, the data were fit to a single class of binding site model, and the best fit parameters for N (stoichiometry), <italic>K<sub>d</sub></italic>, and &#916;<italic>H</italic>, along with the error estimates of the fit, are provided as an <italic>inset</italic> to each panel. &#916;<italic>S</italic> is a secondarily calculated value, and thus there is no error estimate. The reciprocal experiments in which C3dg was titrated into Sbi-IV or Sbi-III-IV were also performed (results summarized in <xref ref-type="table" rid="tbl2">Table 2</xref>).</p></caption><graphic xlink:href="zbc0350846530003"/></fig>
FIGURE 3.Isothermal titration calorimetry analyses of the Sbi-IV:C3dg (A) and Sbi-III-IV:C3dg (B) interactions. In A, the concentration of C3dg in the cell was 10.4 mum, and the concentration of the Sbi-IV injectant in the syringe was 203 mum. In B, the concentration of C3dg in the cell was 12.0 mum, and the concentration of the Sbi-III-IV injectant in the syringe was 173 mum. In each case, the data were fit to a single class of binding site model, and the best fit parameters for N (stoichiometry), Kd, and DeltaH, along with the error estimates of the fit, are provided as an inset to each panel. DeltaS is a secondarily calculated value, and thus there is no error estimate. The reciprocal experiments in which C3dg was titrated into Sbi-IV or Sbi-III-IV were also performed (results summarized in Table 2).
###end p 41
###begin p 42
###xml 62 63 62 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 86 87 86 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 0 102 0 102 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Isothermal titration calorimetry analyses of the Sbi-IV:C3dg (<italic>A</italic>) and Sbi-III-IV:C3dg (<italic>B</italic>) interactions.</bold>
###xml 106 107 106 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 158 159 157 158 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 232 233 230 231 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 238 239 236 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 290 291 287 288 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 368 369 364 365 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 496 497 492 493 <sub xmlns:xlink="http://www.w3.org/1999/xlink">d</sub>
###xml 495 497 491 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K<sub>d</sub></italic>
###xml 508 509 500 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 573 578 565 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink">inset</italic>
###xml 599 600 587 588 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 796 803 784 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="tbl2">Table 2</xref>
Isothermal titration calorimetry analyses of the Sbi-IV:C3dg (A) and Sbi-III-IV:C3dg (B) interactions. In A, the concentration of C3dg in the cell was 10.4 mum, and the concentration of the Sbi-IV injectant in the syringe was 203 mum. In B, the concentration of C3dg in the cell was 12.0 mum, and the concentration of the Sbi-III-IV injectant in the syringe was 173 mum. In each case, the data were fit to a single class of binding site model, and the best fit parameters for N (stoichiometry), Kd, and DeltaH, along with the error estimates of the fit, are provided as an inset to each panel. DeltaS is a secondarily calculated value, and thus there is no error estimate. The reciprocal experiments in which C3dg was titrated into Sbi-IV or Sbi-III-IV were also performed (results summarized in Table 2).
###end p 42
###begin p 43
###xml 0 86 0 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Efb Residues Important for C3d Binding Align with the Corresponding Residues in Sbi-IV</italic>
###xml 264 270 260 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4</xref>
###xml 479 481 471 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref12">12</xref>
Efb Residues Important for C3d Binding Align with the Corresponding Residues in Sbi-IV-The sequence identity between Sbi-IV (69 residues) and Efb-C (72 residues) is only 19% over a 43-residue stretch, with five of eight identical residues located in helix alpha2 (Fig. 4). Despite the low sequence identity, Sbi-IV helix alpha2 residues Arg-231 and Asn-238 align with two Efb residues, Arg-131 and Asn-138, that are particularly important for formation of the Efb-C-C3d complex (12). Two other Efb residues that contact C3d, His-130 and Lys-135, are conservatively substituted by arginines in Sbi-IV. In the Efb-C-C3d complex, Arg-131 lies deep in an acidic pocket of C3d, and Asn-138 is involved in an intermolecular hydrogen bonding network. Alignment with Arg-131 and Asn-138 of Efb suggests that Sbi residues Arg-231 and Asn-238 are key residues for Sbi interaction with C3.
###end p 43
###begin p 44
###xml 0 56 0 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R231A and N238A Mutations Abolish Sbi-IV Binding to C3dg</italic>
###xml 410 416 410 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5</xref>
###xml 460 466 460 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6</xref>
###xml 724 726 724 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref12">12</xref>
###xml 858 860 858 860 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref13">13</xref>
###xml 878 879 877 878 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 946 947 944 945 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 974 976 972 974 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref23">23</xref>
###xml 1064 1065 1061 1062 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
R231A and N238A Mutations Abolish Sbi-IV Binding to C3dg-As a consequence of the sequence alignment results mentioned in the previous section, Sbi-IV R231A and Sbi-IV N238A single mutants and Sbi-IV R231A-N238A double mutant were made. As shown by affinity pulldown experiments, both single and double mutations effectively abolished binding between Sbi-IV and C3dg-containing C3 derivatives present in serum (Fig. 5). This was confirmed in an SPR experiment (Fig. 6), where the binding interaction between Sbi-IV and biosensor-bound C3dg was abolished when any of the Sbi-IV single or double mutants was used as an analyte. A similar effect was previously observed upon double mutation of Efb residues Arg-131 and Asn-138 (12), but the results of similar experiments with Ehp were complicated by the presence of a second lower affinity binding site on Ehp (13). At about 0.6 mum when Sbi-IV is the analyte (this study, data not shown) and 0.8 mum when C3dg is the analyte (23), the wild-type Sbi-IV:C3dg affinity measured by SPR is slightly lower than the 0.35 mum affinity measured by ITC (see above). This may simply reflect the superimposed surface effects of SPR due to the need to chemically couple one of the binding partners to the biosensor surface, relative to the pure solution phase interaction measured in the ITC experiment.
###end p 44
###begin p 45
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 4.</label>
###xml 9 67 9 67 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Sequence alignment of Sbi-IV, Efb-C, Ehp, SCIN, and SpA-B.</bold>
###xml 225 241 225 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green rectangles</italic>
###xml 9 358 9 358 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="46"><bold>Sequence alignment of Sbi-IV, Efb-C, Ehp, SCIN, and SpA-B.</bold> The secondary structure elements of Sbi-IV are shown. The amino acid sequence numbers are for Sbi-IV. Sbi-IV residues Arg-231 and Asn-238 are highlighted by <italic>green rectangles</italic>; the corresponding Efb-C residues are Arg-131 and Asn-138, and the corresponding Ehp residues are Arg-75 and Asn-82.</p>
###xml 9 358 9 358 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="46"><bold>Sequence alignment of Sbi-IV, Efb-C, Ehp, SCIN, and SpA-B.</bold> The secondary structure elements of Sbi-IV are shown. The amino acid sequence numbers are for Sbi-IV. Sbi-IV residues Arg-231 and Asn-238 are highlighted by <italic>green rectangles</italic>; the corresponding Efb-C residues are Arg-131 and Asn-138, and the corresponding Ehp residues are Arg-75 and Asn-82.</p></caption>
###xml 358 358 358 358 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0350846530004"/>
###xml 0 358 0 358 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig4"><label>FIGURE 4.</label><caption><p textid="46"><bold>Sequence alignment of Sbi-IV, Efb-C, Ehp, SCIN, and SpA-B.</bold> The secondary structure elements of Sbi-IV are shown. The amino acid sequence numbers are for Sbi-IV. Sbi-IV residues Arg-231 and Asn-238 are highlighted by <italic>green rectangles</italic>; the corresponding Efb-C residues are Arg-131 and Asn-138, and the corresponding Ehp residues are Arg-75 and Asn-82.</p></caption><graphic xlink:href="zbc0350846530004"/></fig>
FIGURE 4.Sequence alignment of Sbi-IV, Efb-C, Ehp, SCIN, and SpA-B. The secondary structure elements of Sbi-IV are shown. The amino acid sequence numbers are for Sbi-IV. Sbi-IV residues Arg-231 and Asn-238 are highlighted by green rectangles; the corresponding Efb-C residues are Arg-131 and Asn-138, and the corresponding Ehp residues are Arg-75 and Asn-82.
###end p 45
###begin p 46
###xml 0 58 0 58 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Sequence alignment of Sbi-IV, Efb-C, Ehp, SCIN, and SpA-B.</bold>
###xml 216 232 216 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green rectangles</italic>
Sequence alignment of Sbi-IV, Efb-C, Ehp, SCIN, and SpA-B. The secondary structure elements of Sbi-IV are shown. The amino acid sequence numbers are for Sbi-IV. Sbi-IV residues Arg-231 and Asn-238 are highlighted by green rectangles; the corresponding Efb-C residues are Arg-131 and Asn-138, and the corresponding Ehp residues are Arg-75 and Asn-82.
###end p 46
###begin p 47
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 5.</label>
###xml 9 39 9 39 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Serum affinity pulldown assay.</bold>
###xml 410 411 410 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 451 452 439 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">L</italic>
###xml 513 524 489 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink">fourth lane</italic>
###xml 577 582 553 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink">fifth</italic>
###xml 587 598 563 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sixth lanes</italic>
###xml 799 810 775 786 <italic xmlns:xlink="http://www.w3.org/1999/xlink">three lanes</italic>
###xml 9 913 9 889 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="48"><bold>Serum affinity pulldown assay.</bold> SDS-PAGE analysis of an affinity pulldown assay with human serum as prey and various individual and combined Sbi domains as bait proteins immobilized on an NHS-Sepharose column. Captured proteins were identified by MALDI-TOF. The first lane is a ladder of molecular weight marker proteins with molecular weights indicated. The next two lanes show capture of IgG heavy- (<italic>H</italic>, &#8764;50 kDa) and light-chain (<italic>L</italic>, &#8764;25 kDa) fragments by Sbi-II and Sbi-I-II. The <italic>fourth lane</italic> shows that Sbi-III fails to capture IgG and C3. The <italic>fifth</italic> and <italic>sixth lanes</italic> show that Sbi-III-IV and Sbi-IV capture fragments of complement component C3 with approximate molecular masses of 119, 75, 65, 43, and 40 kDa (C3 chain origin of the fragments is indicated). The last <italic>three lanes</italic> show that Sbi-IV mutants R231A, N238A, and R231A-N238A fail to capture C3 and instead capture albumin.</p>
###xml 9 913 9 889 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="48"><bold>Serum affinity pulldown assay.</bold> SDS-PAGE analysis of an affinity pulldown assay with human serum as prey and various individual and combined Sbi domains as bait proteins immobilized on an NHS-Sepharose column. Captured proteins were identified by MALDI-TOF. The first lane is a ladder of molecular weight marker proteins with molecular weights indicated. The next two lanes show capture of IgG heavy- (<italic>H</italic>, &#8764;50 kDa) and light-chain (<italic>L</italic>, &#8764;25 kDa) fragments by Sbi-II and Sbi-I-II. The <italic>fourth lane</italic> shows that Sbi-III fails to capture IgG and C3. The <italic>fifth</italic> and <italic>sixth lanes</italic> show that Sbi-III-IV and Sbi-IV capture fragments of complement component C3 with approximate molecular masses of 119, 75, 65, 43, and 40 kDa (C3 chain origin of the fragments is indicated). The last <italic>three lanes</italic> show that Sbi-IV mutants R231A, N238A, and R231A-N238A fail to capture C3 and instead capture albumin.</p></caption>
###xml 913 913 889 889 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0350846530005"/>
###xml 0 913 0 889 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig5"><label>FIGURE 5.</label><caption><p textid="48"><bold>Serum affinity pulldown assay.</bold> SDS-PAGE analysis of an affinity pulldown assay with human serum as prey and various individual and combined Sbi domains as bait proteins immobilized on an NHS-Sepharose column. Captured proteins were identified by MALDI-TOF. The first lane is a ladder of molecular weight marker proteins with molecular weights indicated. The next two lanes show capture of IgG heavy- (<italic>H</italic>, &#8764;50 kDa) and light-chain (<italic>L</italic>, &#8764;25 kDa) fragments by Sbi-II and Sbi-I-II. The <italic>fourth lane</italic> shows that Sbi-III fails to capture IgG and C3. The <italic>fifth</italic> and <italic>sixth lanes</italic> show that Sbi-III-IV and Sbi-IV capture fragments of complement component C3 with approximate molecular masses of 119, 75, 65, 43, and 40 kDa (C3 chain origin of the fragments is indicated). The last <italic>three lanes</italic> show that Sbi-IV mutants R231A, N238A, and R231A-N238A fail to capture C3 and instead capture albumin.</p></caption><graphic xlink:href="zbc0350846530005"/></fig>
###xml 93 98 <span type="species:ncbi:9606">human</span>
FIGURE 5.Serum affinity pulldown assay. SDS-PAGE analysis of an affinity pulldown assay with human serum as prey and various individual and combined Sbi domains as bait proteins immobilized on an NHS-Sepharose column. Captured proteins were identified by MALDI-TOF. The first lane is a ladder of molecular weight marker proteins with molecular weights indicated. The next two lanes show capture of IgG heavy- (H, approximately50 kDa) and light-chain (L, approximately25 kDa) fragments by Sbi-II and Sbi-I-II. The fourth lane shows that Sbi-III fails to capture IgG and C3. The fifth and sixth lanes show that Sbi-III-IV and Sbi-IV capture fragments of complement component C3 with approximate molecular masses of 119, 75, 65, 43, and 40 kDa (C3 chain origin of the fragments is indicated). The last three lanes show that Sbi-IV mutants R231A, N238A, and R231A-N238A fail to capture C3 and instead capture albumin.
###end p 47
###begin p 48
###xml 0 30 0 30 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Serum affinity pulldown assay.</bold>
###xml 401 402 401 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 442 443 430 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">L</italic>
###xml 504 515 480 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink">fourth lane</italic>
###xml 568 573 544 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink">fifth</italic>
###xml 578 589 554 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sixth lanes</italic>
###xml 790 801 766 777 <italic xmlns:xlink="http://www.w3.org/1999/xlink">three lanes</italic>
###xml 84 89 <span type="species:ncbi:9606">human</span>
Serum affinity pulldown assay. SDS-PAGE analysis of an affinity pulldown assay with human serum as prey and various individual and combined Sbi domains as bait proteins immobilized on an NHS-Sepharose column. Captured proteins were identified by MALDI-TOF. The first lane is a ladder of molecular weight marker proteins with molecular weights indicated. The next two lanes show capture of IgG heavy- (H, approximately50 kDa) and light-chain (L, approximately25 kDa) fragments by Sbi-II and Sbi-I-II. The fourth lane shows that Sbi-III fails to capture IgG and C3. The fifth and sixth lanes show that Sbi-III-IV and Sbi-IV capture fragments of complement component C3 with approximate molecular masses of 119, 75, 65, 43, and 40 kDa (C3 chain origin of the fragments is indicated). The last three lanes show that Sbi-IV mutants R231A, N238A, and R231A-N238A fail to capture C3 and instead capture albumin.
###end p 48
###begin p 49
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 6.</label>
###xml 9 67 9 67 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Surface plasmon resonance analysis of Sbi-IV:C3dg binding.</bold>
###xml 9 164 9 164 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="50"><bold>Surface plasmon resonance analysis of Sbi-IV:C3dg binding.</bold> SPR sensorgrams are shown for Sbi-IV wild-type and Sbi-IV mutants R231A, N238A, and R231A-N238A.</p>
###xml 9 164 9 164 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="50"><bold>Surface plasmon resonance analysis of Sbi-IV:C3dg binding.</bold> SPR sensorgrams are shown for Sbi-IV wild-type and Sbi-IV mutants R231A, N238A, and R231A-N238A.</p></caption>
###xml 164 164 164 164 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0350846530006"/>
###xml 0 164 0 164 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig6"><label>FIGURE 6.</label><caption><p textid="50"><bold>Surface plasmon resonance analysis of Sbi-IV:C3dg binding.</bold> SPR sensorgrams are shown for Sbi-IV wild-type and Sbi-IV mutants R231A, N238A, and R231A-N238A.</p></caption><graphic xlink:href="zbc0350846530006"/></fig>
FIGURE 6.Surface plasmon resonance analysis of Sbi-IV:C3dg binding. SPR sensorgrams are shown for Sbi-IV wild-type and Sbi-IV mutants R231A, N238A, and R231A-N238A.
###end p 49
###begin p 50
###xml 0 58 0 58 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Surface plasmon resonance analysis of Sbi-IV:C3dg binding.</bold>
Surface plasmon resonance analysis of Sbi-IV:C3dg binding. SPR sensorgrams are shown for Sbi-IV wild-type and Sbi-IV mutants R231A, N238A, and R231A-N238A.
###end p 50
###begin p 51
###xml 0 89 0 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R231A and N238A Mutations Abolish Sbi-IV Inhibition of the Alternative Complement Pathway</italic>
###xml 159 165 159 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7</xref>
###xml 275 281 275 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7</xref>
###xml 403 405 403 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref12">12</xref>
###xml 414 416 414 416 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 487 488 474 475 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 510 511 496 497 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 528 529 513 514 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 541 543 526 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref12">12</xref>
###xml 556 557 540 541 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 567 569 551 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref13">13</xref>
R231A and N238A Mutations Abolish Sbi-IV Inhibition of the Alternative Complement Pathway-Sbi-IV inhibited the alternative pathway in a dose-dependent manner (Fig. 7). All of the R231A, N238A, and R231A-N238A mutations abolished Sbi-IV inhibition of the alternative pathway (Fig. 7) in the same way that double mutation of Efb residues Arg-131 and Asn-138 abolished alternative pathway blockade by Efb (12). The IC50 value for Sbi-IV alternative pathway inhibition was approximately10 mum compared with 0.56 mum for Efb, 0.41 mum for Efb-C (12) and 0.12 mum for Ehp (13).
###end p 51
###begin title 52
DISCUSSION
###end title 52
###begin p 53
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus</italic>
###xml 189 190 189 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref9">9</xref>
###xml 191 193 191 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref11">11</xref>
###xml 195 197 195 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref13">13</xref>
###xml 198 200 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref15">15</xref>
###xml 202 204 202 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref17">17</xref>
###xml 206 208 206 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref20">20</xref>
###xml 210 212 210 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref38">38</xref>
###xml 240 242 240 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref23">23</xref>
###xml 321 323 321 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref21">21</xref>
###xml 333 334 330 331 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 351 353 348 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref22">22</xref>
###xml 502 504 499 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref39">39</xref>
###xml 633 634 627 628 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 651 653 645 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref24">24</xref>
###xml 0 9 <span type="species:ncbi:1280">S. aureus</span>
###xml 491 496 <span type="species:ncbi:9606">human</span>
S. aureus has evolved a complement system subversion strategy incorporating several secreted proteins that inhibit the complement cascade at different points using a variety of mechanisms (9-11, 13-15, 17, 20, 38). Sbi is one such protein (23), although it was originally discovered in the late 1990s as a binder of IgG (21) and beta2-glycoprotein I (22), a membrane adhesion protein implicated in blood coagulation. The same authors subsequently showed that expression of Sbi is induced by human IgG (39). We have recently characterized in some detail the IgG binding properties of Sbi but have found no evidence that Sbi binds beta2-glycoprotein I (24).
###end p 53
###begin p 54
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 7.</label>
###xml 9 65 9 65 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Sbi-IV inhibition of the alternative complement pathway.</bold>
###xml 9 216 9 216 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="55"><bold>Sbi-IV inhibition of the alternative complement pathway.</bold> Dose response residual complement activity for Sbi-IV and Sbi-IV mutants R231A, N238A, and double mutant R231A-N238A were assessed in a Wielisa assay.</p>
###xml 9 216 9 216 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="55"><bold>Sbi-IV inhibition of the alternative complement pathway.</bold> Dose response residual complement activity for Sbi-IV and Sbi-IV mutants R231A, N238A, and double mutant R231A-N238A were assessed in a Wielisa assay.</p></caption>
###xml 216 216 216 216 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0350846530007"/>
###xml 0 216 0 216 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig7"><label>FIGURE 7.</label><caption><p textid="55"><bold>Sbi-IV inhibition of the alternative complement pathway.</bold> Dose response residual complement activity for Sbi-IV and Sbi-IV mutants R231A, N238A, and double mutant R231A-N238A were assessed in a Wielisa assay.</p></caption><graphic xlink:href="zbc0350846530007"/></fig>
FIGURE 7.Sbi-IV inhibition of the alternative complement pathway. Dose response residual complement activity for Sbi-IV and Sbi-IV mutants R231A, N238A, and double mutant R231A-N238A were assessed in a Wielisa assay.
###end p 54
###begin p 55
###xml 0 56 0 56 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Sbi-IV inhibition of the alternative complement pathway.</bold>
Sbi-IV inhibition of the alternative complement pathway. Dose response residual complement activity for Sbi-IV and Sbi-IV mutants R231A, N238A, and double mutant R231A-N238A were assessed in a Wielisa assay.
###end p 55
###begin p 56
###xml 59 61 59 61 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref23">23</xref>
###xml 63 65 63 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref24">24</xref>
###xml 291 293 291 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref24">24</xref>
###xml 742 744 742 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref23">23</xref>
###xml 825 831 825 831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7</xref>
###xml 926 928 926 928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref13">13</xref>
###xml 997 999 997 999 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref12">12</xref>
###xml 100 105 <span type="species:ncbi:9606">human</span>
Sbi modulates both the adaptive and innate immune systems (23, 24). Sbi can form a precipitate with human IgG through interaction between the first two Sbi domains and Fc of IgG. This contrasts with SpA-mediated formation of insoluble immune complexes, which involves Fab in addition to Fc (24). Innate immune modulation involves the third and fourth Sbi domains: Sbi-IV and Sbi-III-IV are both able to bind the central protein of the complement system, C3, through its thioester-containing C3dg and anaphylatoxin C3a subunits. Sbi-III-IV and Sbi-E (containing domains I through IV) both activate the alternative pathway, leading to rapid consumption of C3, whereas neither Sbi-III nor Sbi-IV in isolation significantly activates complement (23); Sbi-IV, indeed, inhibits the alternative pathway in a dose-dependent fashion (Fig. 7). In this respect, Sbi-IV resembles Ehp, which specifically inhibits the alternative pathway (13), and Efb, which operates predominantly on the alternative pathway (12).
###end p 56
###begin p 57
###xml 41 43 41 43 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref12">12</xref>
###xml 51 53 51 53 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref13">13</xref>
###xml 62 64 62 64 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref25">25</xref>
###xml 93 94 93 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">1</xref>
###xml 99 100 99 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">2</xref>
###xml 248 249 248 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">5</xref>
###xml 254 255 254 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">6</xref>
###xml 318 324 318 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7</xref>
###xml 564 566 564 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref23">23</xref>
###xml 777 779 777 779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref12">12</xref>
###xml 1050 1052 1050 1052 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref12">12</xref>
###xml 1054 1056 1054 1056 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref23">23</xref>
###xml 1405 1407 1405 1407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref13">13</xref>
###xml 1820 1826 1820 1826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3</xref>
###xml 1875 1876 1875 1876 <sub xmlns:xlink="http://www.w3.org/1999/xlink">d</sub>
###xml 1874 1876 1874 1876 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K<sub>d</sub></italic>
###xml 1894 1895 1893 1894 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1907 1908 1905 1906 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 2048 2050 2046 2048 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref23">23</xref>
Sbi-IV is structurally similar to Efb-C (12), Ehp (13), SCIN (25), and domains of SpA (Figs. 1 and 2). Mutation of either or both of Sbi-IV residues Arg-231 and Asn-238 to alanine, moreover, essentially abolishes both Sbi-IV binding to C3dg (Figs. 5 and 6) and Sbi-IV inhibition of the alternative complement pathway (Fig. 7). The correlation between abolition of C3dg binding and abolition of alternative pathway inhibition as a result of R231A and N238A mutations further establishes the importance of direct Sbi-C3 interaction for complement subversion by Sbi (23). The effect of the R231A and N238A mutations also indicates that the mode of interaction between Sbi-IV and C3dg has similarities with that observed for Efb-C in the crystal structure of its complex with C3d (12), although the sequence identity between Sbi-IV and Efb-C of 19% makes it difficult to assess whether Sbi and Efb have evolved a similar interface with C3d by convergent or divergent evolution. Notably, both Efb and Sbi have a binding preference for native C3 over C3b (12, 23). Analysis of the Ehp-C3d interaction by mutation and isothermal titration calorimetry indicated that Ehp has two binding sites for C3d, a high affinity site resembling that of Efb and a low affinity site that retains an asparagine corresponding to Asn-238 in Sbi and Asn-138 in Efb but lacks the arginine corresponding to Sbi Arg-231/Efb Arg-131 (13). This two site binding by Ehp was ascribed to the presence of tandem repeats of -AQ(K/R)AVNL-. Although there is a repeat of sorts in Sbi-IV (-RVKSAND- at positions 210-216 and -AQREVNK- at positions 233-239), the repeat similarity is much weaker and sequence spacing between the repeats is four residues longer than in Ehp. As expected then, analysis of the Sbi-IV:C3dg and Sbi-III-IV:C3dg interaction by ITC (Fig. 3) indicates that the stoichiometry is 1:1 (with Kd values of 0.35 mum and 0.28 mum for Sbi-IV:C3dg and Sbi-III-IV:C3dg), and as was the case in our earlier SPR measurements of the binding affinity between Sbi-IV and C3dg (23), the ITC data were well fit to a single class of binding site model.
###end p 57
###begin p 58
###xml 6 8 6 8 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 72 73 71 72 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 95 96 93 94 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 113 114 110 111 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 126 128 123 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref12">12</xref>
###xml 141 142 137 138 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 152 154 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref13">13</xref>
###xml 285 287 281 283 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 331 332 326 327 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 341 342 335 336 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 344 346 338 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref23">23</xref>
###xml 517 519 511 513 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
The IC50 value for Sbi-IV inhibition of the alternative pathway is 10 mum compared with 0.56 mum for Efb, 0.41 mum for Efb-C (12) and 0.12 mum for Ehp (13), indicating that Sbi-IV is less efficient as an inhibitor of the alternative pathway than Efb and Ehp. The previously measured IC50 values for Sbi-III-IV and Sbi-E were 0.1 mum and 2 mum (23), the lower values than Sbi-IV reflecting the occurrence of rapid C3 consumption in addition to inhibition of the alternative pathway. Taken together, the affinity and IC50 results suggest that, while the mutation data discussed above imply that the Sbi-IV-C3 and Efb-C3 interactions share important characteristics, there are also differences that may have functional significance.
###end p 58
###begin p 59
###xml 80 81 80 81 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 83 85 83 85 <sup xmlns:xlink="http://www.w3.org/1999/xlink">15</sup>
###xml 923 925 923 925 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref23">23</xref>
###xml 1569 1571 1569 1571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref40">40</xref>
###xml 1573 1575 1573 1575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref41">41</xref>
The role of Sbi-III in Sbi function is intriguing. Sbi-III does not bind C3 and 1H-15N HSQC NMR spectra indicate that isolated Sbi-III is natively unfolded, and it remains so when combined with Sbi-IV in the Sbi-III-IV construct, yet the presence of Sbi-III is essential for Sbi activation of the alternative pathway with resulting consumption of C3. (Any effect of other domains of Sbi on the conformation of Sbi-III remains to be investigated.) When Sbi-III-IV but not Sbi-IV is incubated with serum, a significant fraction of the C3 activated becomes covalently bound to Sbi-III-IV, presumably via the C3d thioester. Thus it seems that Sbi-III provides the transacylation target hydroxyl group for Sbi-C3b covalent adduct formation (only the nascently activated C3b form of C3 can undergo covalent adduct formation). A hypothesis as to how Sbi-III:C3 covalent adduct formation leads to C3 consumption has been proposed (23). Specifically, the Sbi-III:C3 adduct may provide a nidus for the assembly of the alternative pathway C3 convertase, C3bBb, that is at least transiently resistant to inactivation by the serum regulatory molecules fH and fI, thereby facilitating the consumptive cleavage of C3. The N-terminal domains Sbi-I and Sbi-II may further assist in the complement consumption process by recruiting IgG molecules that are also suitable targets for transacylation by C3b. Previous studies have shown that alternative pathway C3 convertases covalently attached to IgG are in a protected environment with respect to their rate of inactivation by fH and fI (40, 41).
###end p 59
###begin p 60
###xml 52 54 52 54 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref11">11</xref>
###xml 56 58 56 58 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref12">12</xref>
###xml 70 72 70 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref13">13</xref>
###xml 135 144 135 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus</italic>
###xml 231 234 231 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sbi</italic>
###xml 396 398 396 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref24">24</xref>
###xml 135 144 <span type="species:ncbi:1280">S. aureus</span>
###xml 167 172 <span type="species:ncbi:9606">human</span>
###xml 173 181 <span type="species:ncbi:9606">patients</span>
###xml 282 287 <span type="species:ncbi:9606">human</span>
###xml 300 303 <span type="species:ncbi:9823">pig</span>
###xml 305 308 <span type="species:ncbi:9913">cow</span>
###xml 310 314 <span type="species:ncbi:9925">goat</span>
###xml 321 327 <span type="species:ncbi:9986">rabbit</span>
###xml 773 778 <span type="species:ncbi:9606">human</span>
###xml 891 896 <span type="species:ncbi:9606">human</span>
To date the C3 binding characteristics of Sbi, Efb (11, 12), and Ehp (13) have been examined using recombinant proteins generated from S. aureus strains isolated from human patients. We have compared the nucleotide sequences of 23 sbi genes from a sample of 28 strain isolates from human and animal (pig, cow, goat, ewe, rabbit, and poultry) hosts plus those from five complete genome sequences (24). No changes at all occurred in Sbi-III and very few changes occurred in Sbi-IV. The positions of the Sbi-IV polymorphic amino acids (222-224 and 244-246) correspond to the loop between helices alpha1 and alpha2 and the alpha2-alpha3 loop and N terminus of helix alpha3. This conservation of Sbi-III and Sbi-IV amino acid sequences across more than 30 strains isolated from human and animal hosts suggests that the unique mechanism of complement system subversion by Sbi is a feature of both human and animal infections.
###end p 60
###begin p 61
###xml 106 115 106 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus</italic>
###xml 203 204 203 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref9">9</xref>
###xml 222 224 222 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref12">12</xref>
###xml 232 234 232 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref13">13</xref>
###xml 247 249 247 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref25">25</xref>
###xml 106 115 <span type="species:ncbi:1280">S. aureus</span>
Identification of the structures and active sites of the small complement inhibitory proteins secreted by S. aureus has lead to consideration of the potential therapeutic exploitation of these proteins (9), including Efb (12), Ehp (13), and SCIN (25). Like Efb and Ehp, it appears that a discrete region of the surface of Sbi-IV involving a handful of residues forms the interface with C3, the central protein of the complement system. Sbi-IV itself is therefore a potentially attractive basis either for structure-based design of small molecule or peptide-based therapeutic molecules or for development of protein-based therapeutics for complement-mediated acute inflammatory diseases.
###end p 61
###begin title 62
Supplementary Material
###end title 62
###begin title 63
[Supplemental Data]
###end title 63
###begin p 64
###xml 69 78 <span type="species:ncbi:1280">S. aureus</span>
We thank Prof. M. C. Enright (Imperial College London) for providing S. aureus genomic DNA. The Wellcome Trust is acknowledged for purchase of the 600 MHz NMR spectrometer (Grant 051902) used in this study.
###end p 64
###begin p 65
###xml 80 89 80 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus</italic>
###xml 296 298 296 298 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 772 786 772 786 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus</italic>
###xml 80 89 <span type="species:ncbi:1280">S. aureus</span>
###xml 830 833 <span type="species:ncbi:12227?0.9375">TEV</span>
###xml 835 853 <span type="species:ncbi:12227">tobacco etch virus</span>
The abbreviations used are: Efb, extracellular fibrinogen-binding protein; Sbi, S. aureus binder of immunoglobulin; AP, alternative pathway; CP, classical pathway; Efb-C, complement inhibitory C-terminal domain of Efb; Ehp, Efb homologous protein; HSQC, heteronuclear single quantum coherence; IC50, half-maximal inhibitory concentration; ITC, isothermal titration calorimetry; NOE, nuclear Overhauser effect; NOESY, nuclear Overhauser effect spectroscopy; r.m.s.d., root mean square deviation; RU, response units; Sbi-I, Sbi domain I (42-94); Sbi-II, Sbi domain II (92-156); Sbi-III, Sbi domain III (150-205); Sbi-III-IV, Sbi domains III and IV (150-266); Sbi-IV, Sbi domain IV (198-266); Sbi-E, Sbi domains I-IV (28-266); SCIN, staphylococcal complement inhibitor; SpA, Staphylococcus protein A; SPR, surface plasmon resonance; TEV, tobacco etch virus; TOCSY, total correlation spectroscopy; MES, 4-morpholineethanesulfonic acid; PDB, Protein Data Bank.
###end p 65

